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 Summary  
 
Background and Aim: Ingestion of probiotics can modify gut microbiota and alter insulin 
resistance and diabetes development in rodents. We hypothesized that daily intake of 
Lactobacillus (L.) reuteri increases insulin sensitivity by changing cytokine release and 
insulin secretion via modulation of glucagon-like peptide (GLP-1, GLP-2) release. 
Material and Methods: A prospective, double-blind, randomized trial was performed in 21 
glucose tolerant humans (10 obese; age 51±2 years, BMI 36.0±4.8 kg/m2; 11 lean; 49±4 
years, BMI 23.6±1.9 kg/m2). Participants ingested 1010 L. reuteri or placebo b.i.d. over 4 
weeks. Oral glucose tolerance and isoglycemic glucose infusion tests were used to 
assess GLP-1, GLP-2 and C-peptide secretion, hyperinsulinemic-euglycemic clamps with 
[6,6-2H2]glucose to measure peripheral insulin sensitivity (M-value) and endogenous 
glucose production (EGP). Muscle and hepatic lipid contents were measured by 1H 
magnetic resonance spectroscopy. Immune status was assessed by measuring systemic 
cytokines, high-sensitive C-reactive protein (hsCRP) and lipopolysaccharide (LPS) 
concentrations. 
Results: Intervention did not affect body mass, ectopic fat content and circulating 
cytokines. M was 37% lower (p<0.01) in obese than in lean volunteers, but both M-value 
and EGP did not change upon L. reuteri treatment. However, administration of L. reuteri 
increased glucose-stimulated insulin and C-peptide secretion by 49% (p<0.05) and 55% 
(p<0.05), respectively. Moreover, administration of L. reuteri improved the glucose-
stimulated GLP-1 and GLP-2 release by 76% and 43%, respectively, compared to 
placebo (p<0.05).  
Conclusions: Enrichment of gut microbiota with L. reuteri increased incretin-mediated 
insulin and C-peptide release, without effects on insulin sensitivity in glucose tolerant 
human subjects. These results suggest that modifying the microbiome could increase 
insulin secretion and thereby serve as a novel therapeutic tool for the treatment of type 2 
diabetes. However, further studies are needed to address this issue in this emerging 
research field. 
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 Zusammenfassung 
 
Hintergrund: Die Einnahme von Probiotika führt bei Nagetieren zu einer Modifizierung 
der Darmflora und nachfolgend zu einer Veränderung der Insulinresistenz sowie 
verzögerten Entwicklung eines Diabetes mellitus. Unsere Hypothese lautet, dass es durch 
die tägliche orale Einnahme von Lactobacillus (L.) reuteri über 4 Wochen und die sich 
daraus ergebende Veränderung der menschlichen Darmflora zu einer gesteigerten 
Sekretion der Darmhormone GLP-1, GLP-2, sowie einer verbesserten Insulinsensitivität 
und -Freisetzung kommt.  
Material und Methoden: Eine prospektive, doppelblinde, randomisierte, zweiarmige 
Studie mit 21 Probanden mit normaler Glukosetoleranz (10 adipöse Personen, Alter 51±2 
Jahre, BMI 36,0±4,8 kg/m2, 11 schlanke Personen, Alter 49±4 Jahre, BMI 23,6±1,9 kg/m2) 
wurde durchgeführt. Die Probanden nahmen konstitutiv zweimal täglich 1010 L. reuteri 
oder Plazebo über 4 Wochen ein. Ein isoglykämischer i.v. Glukoseinfusionstest analog zu 
den Blutzuckerspiegeln des vorausgegangen oralen Glukosetoleranztests wurde 
durchgeführt, um den Inkretineffekt sowie die Insulinsekretion zu untersuchen. Zur 
Messung der peripheren (M-Wert) und hepatischen Insulinsensitivität (endogene Glucose-
produktion, EGP) wurde ein euglykämischer-hyperinsulinämischer Clamp unter Einsatz 
eines nicht-radioaktiven Tracer (6,6[2H2]Glukose) durchgeführt. Ektope Fetteinlagerungen 
in Muskel und Leber wurden mittels 1H Magnetresonanzspektroskopie (MRS) gemessen. 
Der systemische Immunstatus wurde anhand systemischer Spiegel von Zytokinen, hoch 
sensitivem C-reaktivem Protein (hsCRP) und Lipopolysaccarid (LPS) erfasst. 
Ergebnisse: Die 4-wöchige Einnahme von L. reuteri hatte keinen messbaren Einfluss auf 
Körpergewicht und Körperfettanteil. Der M-Wert von adipösen Probanden war 37% 
niedriger (p<0,01) verglichen mit dem der schlanken Teilnehmer, jedoch blieben M-Wert 
und EGP unter der Intervention mit L. reuteri oder Plazebo unverändert. Die Einnahme 
von L. reuteri führte jedoch zu einer Glucose-stimulierten Erhöhung der Insulin- (49%, 
p<0,05) und C-Peptid- Sekretion (55%, p<0,05). Desweiteren führte die Einnahme von L. 
reuteri zu einer Erhöhung von Glucose-stimulierten GLP-1 und GLP-2 um 76% bzw. 43% 
(p<0,05) verglichen zur Plazebo-Gruppe.  
Zusammenfassung: Die tägliche Einnahme von L. reuteri über 4 Wochen erhöht Inkretin-
vermittelt die Insulin- und C-Peptid-Sekretion, ohne jedoch die Insulinsensitivität der 
glukosetoleranten Probanden zu beeinflussen. Das lässt vermuten, dass die probiotische 
Modulation der Darmflora die Insulinsekretion verbessert und somit als therapeutischer 
Ansatz bei Personen mit Diabetes Anwendung finden könnte. Im Hinblick auf die aktuelle 
und durchaus kontroverse Informationslage in diesem Forschungsgebiet bedarf es 
weiterer Studien, um diesen Effekt von Probiotika noch genauer zu untersuchen.  
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Abbreviations 
 
APE atom percent enrichment 
AUC area under curve 
BMI body mass index 
CFU colony forming unit 
CRP C-reactive protein 
DAG diacylglycerol 
DI disposition index  
DDZ  german diabetes center 
DPP4 dipeptidyl peptidase 4 
EDTA ethylendiamintetraacetat 
FFA free fatty acids 
GC-MC gas chromatography-mass spectrometry 
GIP gastric inhibitory polypeptide or glucose-dependent insulinotropic peptide 
GLP-1 glucagon-like peptide-1 
GLP-2 glucagon-like peptide-2 
GOT glutamic oxaloacetic transaminase 
GPR G-protein-coupled receptor  
GPT glutamic pyruvate transaminase 
HCL hepatocellular lipids 
hsCRP high-sensitive C-reactive protein 
IcCE individual calibration control evaluation 
IFG impaired fasting glucose 
IGT  impaired glucose tolerance  
IGF-1 insulin-like growth factor-1 
IMCL intramyocellular lipids 
IQR interquartile range 
IRS-1 /-2 insulin-receptor substrate 
ISR insulin secretion 
i.v. intra venous 
ivGTT intra venous glucose tolerance test 
LAL limulus amebocyte lysate 
LBP lipopolysaccharide-binding protein 
LCFA long-chain fatty acids 
LPS lipopolysaccharide 
MRI magnetic resonance imaging 
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MRS magnetic resonance spectroscopy 
NAFLD non-alcoholic fatty liver disease 
NGT normal-glucose tolerance 
OGIS oral glucose sensitivity index 
OGTT oral glucose tolerance test 
PCR polymerase chain reaction 
PI3K phosphatidylinositol 3-kinase 
PKC protein kinases C 
REE resting energy expenditure 
ROS reactive oxygen species 
RQ respiratory quotient 
RT room temperature 
SCFA short-chain fatty acid 
SD standard deviation 
SEM  standard error of the mean 
TG triglycerides  
TLR toll-like receptor 
T2D type 2 Diabetes 
VCO2 carbon dioxide production 
VO2 oxygen consumption 
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Introduction  
 
The role of insulin resistance and secretion in type 2 diabetes 
In 2010 about 285 million people were suffering from diabetes and this number is 
expected to increase to more than 550 million by the year 2030 (IDF, 2011; Shaw et al., 
2010; Nolan et al., 2011). Type 2 diabetes (T2D), formerly known as non-insulin 
dependent diabetes mellitus (NIDDM), is the most prevalent form and accounts for about 
90% of diabetes cases (ADA, 2010). The prevalence of T2D is assumed to increase due 
to population growth, aging and urbanization. It is expected that diabetes incidence, which 
already reached epidemic dimensions, will continue to increase (Chan et al., 2009; Roglic 
et al., 2005; Wild et al., 2004).  
T2D results from decreased insulin sensitivity in combination with insufficient insulin 
secretion. When individuals are insulin-resistant and have lost approximately 65% of their 
β-cell function, T2D becomes overt (Meier et al., 2012; Abdul-Ghani et al., 2006a; Abdul-
Ghani et al., 2010; Abdul-Ghani et al., 2006b; Ferrannini et al., 2005; Defronzo, 2009; 
Defronzo, 2004) (figure 1). Moreover, T2D is associated with reduced incretin 
concentrations as well as incretin effects (Toft-Nielsen et al., 2001; Vilsboll et al., 2001; 
Meier et al., 2001; Nauck et al., 1986), resulting in an impaired insulin secretion in 
response to glucose. In particular, the first-phase of insulin secretion (ISR) is diminished in 
T2D, indicating the important role of incretins as amplifiers of first-phase ISR (Woerle et 
al., 2012). 
The recent increase in the global incidence of T2D, which is observed in Western 
countries and developing nations, suggests that most cases of this disease are caused by 
changes in environmental factors. Major risk factors for T2D such as overnutrition and low 
dietary fibre involve the gut and have been found to be associated with increased insulin 
resistance, decreased glucose tolerance and local or systemic low-grade inflammation 
(Kolb and Mandrup-Poulsen, 2010). Obesity has also been shown to associate with 
altered gut microbiota (Ley et al., 2005; Turnbaugh et al., 2006) which differs in patients 
with T2D compared to non-diabetic subjects (Larsen et al., 2010). In a metagenome-wide 
association study of gut microbiota it has be shown that patients with type 2 diabetes were 
characterized by a moderate degree of gut microbial dysbiosis, accompanied by 
increased abundance of opportunistic pathogenic bacteria (Qin et al., 2012).  
 
Peripheral and hepatic insulin resistance 
Insulin resistance is described as the fundamental failure to respond appropriately to 
insulin. Insulin resistance mainly affects the target tissues of insulin, particularly skeletal 
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muscle and liver, but also adipose tissue and brain (Szendroedi et al., 2012; Szendroedi 
et al., 2011; Bonnet et al., 2011; Harford et al., 2011; Ruan and Lodish, 2003; Ferrannini 
et al., 2005; Abdul-Ghani et al., 2006b; Banks et al., 2012).  
Currently, it is under debate whether the peripheral (muscle) or the hepatic insulin 
resistance occurs first. Skeletal muscle is mainly responsible for whole-body insulin 
resistance, in terms of dysfunction of cellular mechanism to respond appropriately to 
insulin. Skeletal muscle insulin resistance and the resulting reduction of peripheral 
glucose uptake seems to develop early, as shown by studies in young lean individuals 
with muscle-specific insulin resistance (Petersen et al., 2007). As a consequence, glucose 
is redirected to the liver, which increases de-novo-lipogenesis with consecutive 
impairment of hepatic energy metabolism (Samuel and Shulman, 2012; Szendroedi et al., 
2011; Defronzo and Tripathy, 2009).  
However, it has also been suggested that hepatic insulin resistance is the primary event 
initiating to the development of diabetes. Previously, it has been revealed that disruption 
of hepatic insulin signaling results in fasting and postprandial hyperglycemia and the 
subsequent development of peripheral insulin resistance (Michael et al., 2000; Takamura 
et al., 2012).  
 
Metabolic and environmental factors affecting insulin resistance 
The link between elevated lipid levels and insulin resistance is widely accepted. Increased 
availability of free fatty acids (FFA) and subsequent ectopic intracellular lipid accumulation 
may trigger the development of insulin resistance. Particularly, an increased intracellular 
lipid contents in skeletal muscle and liver has been related to insulin resistance (Krssak et 
al., 1999; Szendroedi and Roden, 2009) (figure 1). It was postulated that, in muscle and 
liver, the intracellular accumulation of lipids and diacylglycerol (DAG) triggers the 
activation of novel protein kinases Cs (PKCs) with subsequent impairment of insulin 
signalling. For example, insulin-receptor substrate (IRS) 1-associated phosphatidylinositol 
3-kinase (PI3K) activity is reduced in the muscles of individuals after a lipid infusion. In 
addition, in these individuals the insulin action in the liver, which has some similarities with 
the insulin action in muscle, is associated with defects in insulin signalling in the state of 
hepatic steatosis. Increased liver lipid content further impairs the ability of insulin to 
regulate gluconeogenesis and activate glycogen synthesis (Samuel et al., 2010; Samuel 
and Shulman, 2012). 
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Several other aspects including genetic factors, have been described to contribute to 
alterations of insulin resisitance, (Meigs et al., 2000; Pierce et al., 1995; Kaprio et al., 
1992; Poulsen et al., 1999; Pratley, 1998; Herder and Roden, 2011; Sladek et al., 2007; 
Hemminki et al., 2010; Poulsen et al., 2009; Tattersal and Fajans, 1975). It has been 
demonstrated that first degree relatives of type 2 diabetic subjects have a higher risk to 
develop insulin resistance and subsequent type 2 diabetes (Axelsen et al., 1999; Groop et 
al., 1996; Stumvoll et al., 2005; Pratipanawatr et al., 2001)  
 
 
 
Fig. 1 The current paradigm of the development of type 2 diabetes 
Type 2 diabetes (T2D) is a severe metabolic disorder characterized by a combination of insulin 
resistance and impaired insulin secretion. The development of T2D involves genetic, 
environmental, and lifestyle factors. Insulin resistance occurs in different tissues, mainly in muscle 
and liver and is detectable long before the onset of T2D. Temporarily, insulin resistance can be 
compensated by increased insulin secretion. When β-cells can no longer compensate for the 
insulin resistance a hyperinsulinemic state develops and T2D becomes manifest. Normal glucose 
tolerance (NGT), impaired glucose tolerance (IGT), impaired fasting glucose (IFG). For further 
details see main text. Adapted from (Kendall et al., 2009). 
 
Adiposity, inflammation, and lifestyle factors including dietary habits and physical activity 
also contribute to the development of insulin resistance and subsequently to type 2 
diabetes.  
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Adiposity contributes to T2D development in two aspects. On one hand insulin resistance 
of adipose tissue insulin resistance and elevated lipolysis increase levels of circulating 
FFA and thereby contribute to the development of insulin resistance as described above 
(Kashyap and Defronzo, 2007; Szendroedi and Roden, 2009). On the other hand, adipose 
tissue is an endocrine organ which secretes hormones such as adiponectin and leptin as 
well as cytokines and chemokines (Rosen and Spiegelman, 2006; Fantuzzi, 2005; Wellen 
and Hotamisligil, 2005; Samaras et al., 2010; Guilherme et al., 2008) contributing to the 
subclinical inflammation, associated with the development of T2D (Spranger et al., 2003; 
Herder et al., 2005b; Herder et al., 2009a; Carstensen et al., 2010; Meier et al., 2002; 
Pradhan et al., 2001).  
Dietary habits of the western lifestyle, such as consumption of fast food, are associated 
with insulin resistance (Pereira et al., 2005). In addition, high-fat diet (Badin et al., 2013; 
Atkinson et al., 2013; Lottenberg et al., 2012) and reduced consumption of dietary fiber, 
especially cereals and / or carbohydrates with low glycaemic index are associated with 
insulin resistance (Breneman and Tucker, 2012; Brockman et al., 2012; Cloetens et al., 
2012; Pal and Radavelli-Bagatini, 2012; Parnell and Reimer, 2012; Roelofsen et al., 2010; 
Robertson et al., 2003; Pereira et al., 2002; Weickert et al., 2006a). The consumption of 
dietary fiber has been suspected beneficial in several aspects. It can increase the 
production of short-chain fatty acids (SCFA) in the colon by increased bacterial 
fermentation of indigestible dietary fibers which in turn may improve lipid homeostasis and 
reduce hepatic glucose output (Galisteo et al., 2008). These metabolic alterations are 
mediated by the secretion of gastrointestinal hormones like ghrelin, peptide YY (PYY), 
and glucose-dependent insulinotropic peptide (GIP) with subsequent alteration of satiety 
(Weickert et al., 2006b; Heini et al., 1998; Weickert et al., 2005; Robertson et al., 2003; 
Schenk et al., 2003; Qi et al., 2005). Hence, the mechanisms through which these 
different diets promote the progression to insulin resistance and consecutively towards a 
pre-diabetic state involve a complex physiology of glucose homeostasis (Thomas and 
Pfeiffer, 2012). 
Physical activity also seems to have a strong impact on glucose homeostasis. As 
mentioned above, there is an association of altered skeletal muscle mitochondrial function 
and changes in hepatic glucose and lipid metabolism subsequent to altered insulin 
sensitivity. Several studies described that physical activity protects from insulin resistance 
and T2D, by reversing the negative effects of insulin resistance on skeletal muscle and 
liver (Rabol et al., 2011; Phielix et al., 2012; Phielix et al., 2011; Boushel et al., 2007; 
Mogensen et al., 2007; Kelley et al., 2002; Dela et al., 1995; Manson et al., 1991; King et 
al., 1987). 
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Clinical manifestation of insulin resistance 
Insulin resistance is detectable several years before the diagnosis of diabetes and is 
initially compensated by increased insulin secretion (Tabak et al., 2009; Ferrannini et al., 
2005). T2D manifests when high insulin demand resulting from insulin resistance is no 
longer compensated by the β-cells (Ferrannini, 2009) (figure 1). As demonstrated by the 
Whitehall II study, insulin sensitivity is decreased up to 87% during the five years period 
before diabetes diagnosis. The fasting and the 2h postprandial glucose level increased 
linearly three years before T2D manifestation, and the β-cell function, determined by 
HOMA, showed first pathological increases three to four years before diabetes 
manifestation, followed by a decrease up to 63% until diagnosis (Tabak et al., 2009). 
Additionally, insulin resistance can also be observed in individuals with normal-glucose 
tolerance (NGT), in first degree relatives of subjects with type 2 diabetes, and in 
individuals with impaired fasting glucose (IGT) (Abdul-Ghani et al., 2006b; Weyer et al., 
2001; Lillioja et al., 1988; Saad et al., 1988) and predicts the development of glucose 
intolerance and T2D (Weyer et al., 2001; Abdul-Ghani and Defronzo, 2009).  
 
Insulin secretion and β-cell function as contribuiting factors in the development of type 2 
diabetes 
The β-cells of the islet of Langerhans in the pancreas secrete insulin dependent on actual 
blood glucose concentrations. In insulin-resistant states, β-cells produce increased 
amounts of insulin to counteract resistance to the hormone in peripheral tissues (figure 
1). When β-cells can no longer compensate the insulin resistance by an hyperinsulinemic 
state, hyperglycemia occurs and T2D becomes clinically manifest (Festa et al., 2006; 
Abdul-Ghani and Defronzo, 2009; Abdul-Ghani et al., 2006a; Abdul-Ghani et al., 2006b; 
Kahn et al., 1989; Kahn et al., 1993).  
In an animal model this concept has been confirmed, demonstrating that knockout of the 
peripheral muscle insulin receptor did not induce a diabetic phenotype (Lauro et al., 
1998), indicating that up-regulation of β-cell activity compensates for insulin resistance 
and may engender normal fasting glucose levels by hyperinsulinemia. In contrast, it has 
been shown, that a β-cell defect in the presence of insulin resistance results in a diabetic 
phenotype (Bergman, 1989; Bruning et al., 1997). 
Furthermore, the development of β-cell dysfunction is associated with the consumption of 
high fat diet, which may be accompanied with higher levels of endogenous FFA. FFA, in 
particular saturated FFA, are potentially lipotoxic to pancreatic β-cells, promote apoptosis 
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(Unger, 2002) and have an impact of cytokine secretion of blood cells (Simon et al., 
2013). 
 
The gastrointestinal hormones and the incretin effect  
Oral glucose administration induces a much greater degree of insulin secretion compared 
to a parenteral isoglycemic intravenous glucose infusion, suggesting that gastrointestinal 
hormones, the incretins play an important role (MCINTYRE et al., 1964; MCINTYRE et al., 
1965). Gastrointestinal hormones like glucose-dependent insulinotropic polypeptide (GIP) 
and glucagon-like peptide-1 (GLP-1) are essentially involved in the regulation of gastric 
acid secretion and gut motility, release of pancreatic enzymes, and nutrient absorption. 
The incretin GLP-1, support the disposal of glucose through the stimulation of insulin 
secretion from the pancreas. This incretin effect is of relevance in the glucose metabolism 
and applied in the treatment of T2D (Drucker, 2006; Drucker and Nauck, 2006; Nauck et 
al., 2004; ELRICK et al., 1964) since it has been described that the overall incretin effect 
in T2D with deteriorated glycaemic control is reduced (Nauck et al., 1986; Nauck et al., 
1993; Calanna et al., 2013).  
 
 
 
 
Fig. 2 Schematic presentation of proglucagon-processing 
Modified from (Rowland and Brubaker, 2008): Synthesis of the 160 amino acid precursor 
protein by the intestinal L-cell. The hormone Glucagon is part of the sequence but is not 
liberated in his active form from the intestinal L-cell.  
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GIP is synthesized from the enteroendocrine K cells, has insulinotropic effects and only 
slight effects on the gastric acid secretion (Dupre et al., 1973). It was the first identified 
incretin, followed by GLP-1.  
GLP-1 and GLP-2 are co-secreted after food intake from intestinal L-cells (figure 2) and 
are rapidly degraded by dipeptidyl-peptidase (DPP)-4. The incretin release is 
interdependent on gastric emptying and blood glucose (Samsom et al., 2009; Drucker, 
2006). Defects of the incretin system in patients with T2D have been tackled by medical 
treatment with incretin analogues or mimetics as well as treatment with DPP-4 inhibitors, 
all of which improve glucose metabolism. GLP-1 improves insulin secretion, inhibits 
glucagon action, has effects on central-nervous-system, and inhibits gastric emptying 
(Drucker and Nauck, 2006; Drucker, 2002).  
GLP-2, an intestinotrophic peptide, enhances intestinal epithelial barrier function by 
affecting both para-cellular and trans-cellular pathways. GLP-2 treatment has been shown 
to increase intestinal weight and mucosal thickness, surface area and cryptic architecture 
in animals and humans (Rowland and Brubaker, 2008; Jeppesen et al., 2005). 
Furthermore, chronic administration of GLP-2 also affects intestinal functions towards an 
increase in nutrient digestion and absorption as well as in barrier function in normal mice 
(Benjamin et al., 2000; Brubaker et al., 1997; Cheeseman, 1997; Kato et al., 1999; 
Drucker, 2002). It has been proposed to treat patients with chronic bowel disease with 
GLP-2 in a clinical setup, as it has been shown to reduce inflammation and enhance 
mucosal integrity in several injury models in rodents. However, as GLP-2 affects cell 
proliferation and differentiation through insulin-like growth factor (IGF)-1 related pathways. 
Therefore, it was proposed to closely monitor patients with known neoplasms during 
treatment with DPP-4 inhibitors, since it has been described that DPP-4 degraded both 
peptides, GLP-1 and GLP-2 (Rowland and Brubaker, 2008; Masur et al., 2006). 
 
Intestinal microbiota and the impact on host metabolism 
Numerous animal studies point to a link between intestinal microbiota, intestinal 
permeability, and chronic inflammation (Sommer and Backhed, 2013; Tremaroli and 
Backhed, 2012). Furthermore mainly in mouse models it has been supposed that 
intestinal microbiota are involved in the regulation of metabolic parameters (Musso et al., 
2010; Lye et al., 2009; Cani and Delzenne, 2009b; Cani et al., 2009b) including insulin 
resistance (Genta et al., 2009), postprandial glucose response (Cani et al., 2009a), 
lllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllll
llllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllll 
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obesity (Parnell and Reimer, 2009) and type 2 diabetes (Qin et al., 2012). However, the 
majority of these studies were performed in animal models, while data from human 
studies are rare.  
 
Gut microbiota and gut hormones (incretins) 
Recently, in rodents it has been demonstrated that the alteration of gut microbiota 
composition affects the intestinotrophic gut hormone glucagon-like peptide (GLP)-2 (Cani 
et al., 2009b) as well as the insulinotropic GLP-1, GIP and PYY (Cani et al., 2009a). 
Cani et al. showed that mice treated with prebiotics leads to have increased GLP-2 levels 
resulting in reduced gut permeability, supposed to increased expression of the tight 
junction proteins like occludin and zona occludens-1 (Cani et al., 2009b; Moran et al., 
2012). The increased GLP-2 release was likely mediated by changes of FFA levels in the 
gut, in particular the SCFA butyrate (Bartholome et al., 2004; Tappenden et al., 2003), 
which is one of the SCFA produced during the fermentation of the prebiotics by the gut 
microbiota (Roberfroid et al., 2010; Ramnani et al., 2012). 
 
Gut microbiota and systemic inflammation 
Another mechanism how defined modulation of the gut microbiota may prevent metabolic 
diseases could be by reducing the translocation and systemic concentrations of the 
endotoxin Lipopolysaccharide (LPS), leading to an altered inflammatory status. It is well 
established that elevated levels of LPS, a component of the outer cell wall of gram-
negative bacteria, in the peripheral blood are associated with low-grade inflammation 
(Caradonna et al., 2000; Cani et al., 2012; Cani and Delzenne, 2009c; Andreasen et al., 
2010b). LPS is a dominant exogenous Toll-like receptor (TLR-)4 ligand, which activates 
the innate immune system (Medzhitov, 2007; Medzhitov, 2001). In an animal study by 
Cani et al., decreased intestinal permeability modulated by prebiotic treatment correlated 
with lower portal plasma LPS concentrations known to trigger inflammation and oxidative 
stress (figure 4). In these mice improved systemic and hepatic inflammation was shown 
(Cani et al., 2009b).  
Since both, cytokines and oxidative stress have been shown to be potentially harmful to 
insulin-producing β-cells, this could be an additional effect. Low-grade inflammation and 
differentially regulated cytokines have been reported in human subjects with diabetes to 
associate with insulin resistance, decreased β-cell function, impaired glucose 
homeostasis, prediabetes, diabetes and obesity (Herder et al., 2009b; Herder et al., 
2009a; Pfleger et al., 2008a; Herder et al., 2007b; Herder et al., 2007a; Herder et al., 
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2005a; Schloot et al., 2007; Kempf et al., 2007). In mice an additional role of leptin, an 
adipokine secreted from the white adipose tissue (Xie et al., 2008), mainly involved in 
energy metabolism (Mantzoros et al., 2011) has been described to alter the intestinal 
translocation of bacteria by modulating the bacterial adherence to the intestinal mucosa 
(Amar et al., 2011). Those observations, mainly from animal studys, indicate that the gut 
microbiota is in important factor to contribute to systemic inflammation and may contribute 
to changes in insulin sensitivity, possibly also in humans.  
 
Metabolic effects of modulated microbiota 
In animal studies altered gut microbiota has been associated by diseases like obesity and 
diabetes and is influenced by weight alterations and dietary intervention (Cani and 
Delzenne, 2009a; Cani et al., 2008b). Ingestion of probiotics in animal experiments and in 
only few human clinical trials has been shown to influence gut microbiota composition 
(Ley et al., 2005; Turnbaugh et al., 2006), intestinal permeability, blood glucose, HbA1c, 
triglyceride and LDL-cholesterol levels (Cani et al., 2007b; Yadav et al., 2007; Hlivak et 
al., 2005), and blood pressure (Sipola et al., 2002; Seppo et al., 2003) (table 1).  
However, in human subjects, the link between alterations of the gut microbiota by 
ingestion of probiotics and factors associated with diabetes or obesity such as insulin 
resistance, β-cell activity, low grade inflammation and altered incretin hormones is less 
well understood.  
At present, it is poorly investigated whether probiotic treatment leads to an alteration of 
ectopic fat distribution which is defined by the deposition of triglycerides within cells of 
non-adipose tissue that normally contain only small amounts of fat (Lettner and Roden, 
2008) focusing particularly on the intracellular lipid contents in skeletal muscle and liver, 
which are directly related to insulin resistance (Szendroedi and Roden, 2009). 
Recently, a preliminary study with ten healthy human subjects has shown that the intake 
of prebiotics over a period of two weeks lead to increased plasma GLP-1 and Peptide YY 
concentrations as well as decreased post prandial glucose concentrations in humans 
(Cani et al., 2009a). To date only one other human study addressed whether the alteration 
of gut microbiota by ingestion of probiotics can influence glucose homeostasis and insulin 
sensitivity, but whether a beneficial effect of probiotics on glucose metabolism in humans 
indeed is related to improved gut integrity (via GLP-2) and to an amelioration of chronic 
systemic inflammation is unknown.  
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Table 1 Metabolic effects of probiotic strains administered to different animal models 
Probiotic strain / 
combinations  Result of intervention Animal model Reference 
L. casei inhibited occurrence of diabetes  modified immune response NOD mice 
(Matsuzaki et 
al., 1997b) 
L.casei plasma glucose  modified immune response NIDDM-KK-Ay mice 
(Matsuzaki et 
al., 1997c) 
L.casei incidence of diabetes  insulin secreting β-cells  
AXN-induced BALB/c 
mice 
(Matsuzaki et 
al., 1997a) 
L. rhamnosus GG 
HbA1c and oxidative stress  
glucose tolerance   
insulin secretion  
STZ-induced diabetic 
rats 
(Tabuchi et al., 
2003)  
L. reuteri GMNL-
263 
HbA1c  
blood glucose  
STZ-induced diabetic 
rats (Lu et al., 2010) 
L. plantarum DSM 
15313 blood glucose  HFD C57BL/6J mice 
(Andersson et 
al., 2010) 
B. longum BIF 
CGMCC no. 2107 
endotoxin   
intestinal inflammation   
intestinal growth factor  
HFD rats  (Chen et al., 2011) 
B. animalis subsp. 
lactis 420 
inflammatory status  
metabolic status  
bacterial translocation  
HFD vs. chaw diet 
C57bl6 ob/ob knock-out 
mice 
(Amar et al., 
2011) 
L. acidophilus 
NCDC14,  
L. casei NCDC19 
diabetic dyslipidemia 
lipid peroxidation  
STZ-induced diabetic 
rats 
(Yadav et al., 
2008) 
L. acidophilus 
NCDC14,  
L. casei NCDC19 
HbA1c and blood glucose  
free fatty acids  
triglycerides  
Fructose-induced 
diabetic rats 
(Yadav et al., 
2007) 
L. acidophilus,  
L. rhamnosus 
B. lactis,  
impoved blood glucose due to 
altered gliclazide transport 
across ileal tissue 
AXN-induced diabetic 
rats 
(Al-Salami et 
al., 2008) 
VSL#3 β-cell destruction and insulitis  IL-10  NOD mice 
(Calcinaro et 
al., 2005)  
VSL#3 
insulin resistance  
hepatic steatosis  
inflammation  
HFD C57BBL-6 mice (Ma et al., 2008)  
Different Lactobacilli (L.) and Bifidobacteria (B) species and their metabolic effects. Streptozotocin 
(STZ), Alloxan (AXN), non-obese diabetic (NOD) mice, non-insulin-dependent diabetes mellitus 
(NIDDM) model, high fat diet (HFD),  means improved / increased,  means reduced / 
decreased. VSL#3 is patented probiotic mixture, containing Bifidobacterium breve, Bifidobacterium 
longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus 
paracasei, Lactobacillus bulgaricus and Streptococcus thermophilus. 
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A recent study by Vrieze et al. investigated the effects of allogenic fecal transplantation of 
lean donors on insulin sensitivity to subjects (n=18) with newly diagnosed metabolic 
syndrome (Vrieze et al., 2012). The fecal infusion from lean donors improved insulin 
resistance as well as fasting lipid levels in obese individuals with metabolic syndrome. 
These results underscore the potential role of gut microbiota on glucose and lipid 
metabolism (Vrieze et al., 2012). Interestingly, donor-feces infusion has recently been 
shown to result in 81% (13 of 16 patients) in resolution of Clostridium difficile associated 
diarrhoe whereas antibiotic therapy with vancomycin results only in 31% (4 of 13 patients) 
in resolution (Van et al., 2013). This suggests that donor-feces infusion might be used as 
a potential therapeutic strategy against recurrent C. difficile infection, which is difficult to 
treat, even with antibiotics (Van et al., 2013). Besides transferring the complex community 
of microorganisms, with poor knowledge of the composition and diversity, the ingestion of 
probiotics might be an alternative (Gerritsen et al., 2011). 
A study with a heterogenous group of participants of 54 males with T2D or with impaired 
or normal glucose tolerance who received L. acidophilus NCFM for 4 weeks showed 
preserved insulin sensitivity compared to the placebo group, but no effect on the systemic 
inflammatory response (Andreasen et al., 2010a). There was considerable variability 
among study participants and it was not reported whether those with improved insulin 
sensitivity were diabetic or normoglycemic.  
Recently, Ejtahed et al. showed that the consumption of a probiotic yogurt containing L. 
acidophilus La5 and Bifidobacterium lactis Bb12 over six weeks improved enzymatic 
antioxidant status, fasting blood glucose level and the HbA1c in patients with type 2 
diabetis compared to the control group which consumed conventional yogurt (Ejtahed et 
al., 2012). The absence of a control group that consumed no yogurt, even in regard to the 
described biological activities of milk proteins (Korhonen and Pihlanto, 2006) could limit 
the generalizability of these results (Ejtahed et al., 2012). 
 
Lactobacillus reuteri 
Probiotic treatment with Lactobacilli and Bifidiobacteria are supposed to benefit of the host 
metabolism in different ways, involving preventative and therapeutic aspects (table 1).  
Probiotics such as Lactobacillus (L.) reuteri has been shown to improve diseases such as 
infant colic (Savino et al., 2007; Indrio et al., 2008), IgE-associated eczema 
(Abrahamsson et al., 2007; Bottcher et al., 2008) and diarrhea (Shornikova et al., 1997b; 
Shornikova et al., 1997a; Weizman et al., 2005). In animal models L. reuteri reduced 
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intestinal inflammation (Liu et al., 2010) and seemed to have an impact on immune 
reactivity measured in vitro (Livingston et al., 2010; Hoffmann et al., 2008).  
 
 
 
Fig. 3 Lactobacillus reuteri  
Colored in blue after a gram stain (100x)  
(private source, foto made at the Institute for Medical Microbiology 
and Hospital Hygiene, Heinrich-Heine-University Düsseldorf, 
Germany 2012, M.C. Simon) 
 
Lactobacillus reuteri is a gram-positive bacterium (figure 3), which also naturally inhabits 
the gut of mammals, and is used by the food industry to prepare probiotic nutrients. L. 
reuteri has been tested for host tolerance in children (Ruiz-Palacios et al., 1992), healthy 
adults (Wolf et al., 1995), and immunosuppressed patients with HIV (Wolf et al., 1998). 
One of the best documented effects of L. reuteri is the treatment of rotavirus-induced 
diarrhea. Treatment of rotaviral diarrhea by consumption of L. reuteri significantly shortens 
the duration of the illness compared to placebo treatment in young children between 6 and 
36 months of age receiving up to 1011 colony-forming units (CFU). This effect was dose-
dependent: the more L. reuteri is consumed, the faster the diarrhea stops (Shornikova et 
al., 1997a; Shornikova et al., 1997b).  
Furthermore, L. reuteri is found in breast milk (Sinkiewicz and Nordström, 2005), and oral 
intake of the mother likewise increases the amount of L. reuteri present in her milk, and 
thus the likelihood that it will be transferred to the child (Abrahamsson et al., 2005). L. 
reuteri benefits its host in a variety of ways, particularly by modulating the immune system 
and has been shown to be safe in application, even in neonates at dosages up to 1010 
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CFU per day. L. reuteri has a well-studied safety and a strong probiotic activity, when 
compared with 46 other strains of Lactobacillus spp. (Jacobsen et al., 1999). 
 
Overall, gut microbiota consisting of complex communities of microorganisms that 
colonise the intestine seem to have an major impact on health and disease (Gerritsen et 
al., 2011) and as recently shown in a metagenome-wide association study, patients with 
T2D are characterized by a moderate but statistically highly significant degree of gut 
microbial dysbiosis (Qin et al., 2012).  
So far, the above mentioned studies demonstrate that alteration of intestinal microbiota 
may affect the host’s metabolic status. However most of the studies investigating the 
effects of prebiotic or probiotic alterd microbiota were performed in animal models. To 
understand the potential impact of probiotic bacterial strains on the composition of the 
human gut microbiota and on the host’s metabolic and immunological status, further 
carefully controlled studies in humans are required.  
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Hypothesis 
The goal of the study was to test the hypothesis that L. reuteri-enriched microbiota 
improve insulin sensitivity and insulin secretion in lean and obese glucose tolerant 
subjects by improving GLP-2 and / or GLP-1 linked insulinotropic effects. 
 
Specific aims 
 
The specific aims were therefore: 
To investigate the effects of L. reuteri-enriched gut microbiota in a prospective, double-
blind, placebo-controlled randomized trial over 8 weeks in human subjects on  
I. insulin sensitivity and β-cell function 
II. incretin concentrations  
III. inflammatory status and reactive oxygen species 
IV. ectopic fat distribution 
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These aims were addressed by the following work packages (WPs; figure 4): 
 
1.WP: Influence of L. reuteri enriched microbiota on insulin sensitivity, β-cell function and 
glucose tolerance: Oral glucose tolerance test (OGTT) provided information on glucose 
tolerance, and was performed in all subjects before, during and after study. Furthermore, 
OGTT provided information of the β-cell function, based on insulin, C-peptide secretion 
and mathematical model calculations (e.g. disposition index, adaptation index). Whole 
body insulin sensitivity was assessed by the gold standard, the hyperinsulinemic-
euglycemic clamp, in combination with a tracer to assess the hepatic insulin sensitivity.  
 
2.WP:  Influence of microbiota on incretins: It was tested whether administration of L. 
reuteri affects gut hormone secretion of intestinotrophic GLP-2, insulinotrop GLP-1 and 
GIP. An OGTT was performed and incretin secretion over time was determined during the 
OGTT up to 180 min after glucose ingestion. Blood glucose, insulin, and incretin 
concentrations from OGTT were compared to the results of an isoglycemic intravenous 
(i.v.) glucose infusion test to address the incretin effect in vivo (Nauck et al., 2004; Meier 
et al., 2001). Gastric emptying influences the release of gut hormones and may be 
disturbed in obese subjects and patients with manifest T2D. To take this into account we 
performed a 13C-octanoic acid breath test in each participant. Additionally, the levels of 
lipopolysaccaride (LPS), which are associated with intestinal permeability, were measured 
in peripheral blood. 
 
3.WP: Inflammatory status and reactive oxygen species: Inflammatory status and reactive 
oxygen species (ROS) were assessed by measuring pro-inflammatory (e.g. C- reactive 
protein (CRP), tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-8, IL-1β, macropahge 
inflammatory protein (MIP)-1β) and regulatory (e.g. IL-10, IL1ra, Interferon-gamma (IFN-
γ)) cytokines and chemokine (monocyte chemotactic protein (MCP)-1, also known as 
CCL2). Serum concentration of thiobarbituric acid (TBARS) as a marker for reactive 
oxygen species (ROS) was determined. Systemic LPS-concentrations were determined 
by the limulus amebocyte lysate (LAL)-Test from serum samples. Furthermore, the 
concentrations of total free fatty acids (FFA) in the blood were measured. 
 
4.WP: Ectopic fat distribution: The quantification of hepatocellular and myocellular 
triglycerides content from 1H-MR spectroscopy (MRS) was measured relative to 
intracellular water content, and calculated as described (Krssak et al., 2004b; Krssak et 
al., 1999; Hwang et al., 2007). Spectra were acquired and processed to assess content of 
intramyocellular lipids using jMRUI or NUTS software according to methods developed 
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and previously applied by the research group (Szendroedi et al., 2011). All magnetic 
resonance (MR) measurements were performed on a 3.0 Tesla (T) whole body clinical 
scanner (Philips achieva X-series, Best, The Netherlands).  
 
 
 
 
Fig. 4 Schematic overview of the probiotic effects 
Specific questions or work packages (WPs) which have been addressed are marked red. 
Continuous lines indicate likely pathways, while the dotted lines represent putative pathways.        
 means improved and  means decreased effects. For further details see main text. 
 23
Material and Methods  
 
Study design  
We performed a double-blind, placebo-controlled, randomized, prospective, longitudinal 
descriptive trial in 10 glucose-tolerant obese participants and 11 healthy lean control 
subjects (matched for age and sex) recruited at the German Diabetes Center (DDZ) in 
Düsseldorf. The study was performed according to the Declaration of Helsinki. All subjects 
provided written informed consent. The single centre study was approved by the ethics 
committee of the University of Duesseldorf and registered at ClinicalTrials.gov Identifier 
NCT01250106.  
After a run-in phase, subjects received Lactobacillus reuteri at a dosage of 2*1010 
organisms, equivalent to microbiota contained in two yogurts a day. As fermented milk 
products contain microbiota, it was mandatory for participating subjects to abstain from 
eating or drinking fermented milk products, especially other probiotic products, during the 
8-week study period. A schematic workflow of the trial is illustrated in figure 5. 
 
 
Fig. 5 Overview of the study design and frequency of visits.  
Clamp studies included hyperinsulinemic-euglycemic clamp with [6,6-2H2]glucose tracer to assess 
peripheral and hepatic insulin sensitivity and isoglycemic i.v. glucose infusion to measure the 
incretin effect. Collection of faecal samples for further analysis, oral glucose tolerance test (OGTT), 
magnetic resonance spectroscopy (MRS), and indirect calorimetry (IC) were performed twice 
during study. 
 
Study participants underwent a run-in phase of 4 weeks after the baseline screening visit 
during which all subjects received placebo. The run-in phase allowed evaluation of the 
effect of participation in the study e.g. on T2D risk factors. Food intake was monitored by 
a validated food frequency questionnaire every four weeks. 
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Type 2 diabetes related metabolic parameters, (gut hormones GLP-2 (non-insulinotropic), 
GLP-1 and GIP (insulinotropic), insulin resistance, β-cell activity (according to Mari 2001), 
body weight, body mass index (BMI), waist circumference, hsCRP, triglycerides (TG), 
cholesterol, LDL-/ HDL-cholesterol, cytokines and chemokines) were measured at the 
time when OGTT was performed. Isoglycemic intravenous glucose infusion and 
hyperinsulinemic-euglycemic clamp was performed within three days after OGTT.  
After 4 weeks, subjects were randomised 1:1 into a placebo and a verum arm in a double-
blind fashion and provided with capsules containing placebo or 1010 Lactobacillus reuteri 
(Nutraceutix, Redmond, WA, USA). They ingested one capsule of placebo or verum in the 
morning and one in the evening daily for 4 consecutive weeks.  
Samples of feces for analysis of gut microbiota were obtained at the start of intervention 
(week 4, end of run-in phase) and at the end of the trial (week 8). Treatment adherence 
was assessed by counting capsules and by screening for Lactobacillus reuteri in gut 
microbiota using quantitative real-time PCR. 
 
Study participants  
 
Inclusion criteria 
Inclusion criteria were an age range of 40 – 65 years, non-smoking, absence of 
gastrointestinal disease, willingness to abstain from intake of fermented milk products 
over a study period of 8 weeks, stable dietary habits at least within the last three months. 
Obese subjects were included with BMI 30-45 kg/m2 and healthy lean control subjects with 
BMI 19-25 kg/m2, matched for sex and age. All subjects had to be glucose tolerant and 
need to show stable fasting blood glucose levels as determined at screening and at the 
start of intervention.  
 
Exclusion criteria 
Subjects were excluded in case of pregnancy, cancer, chronic diseases, antibiotic 
therapy, competitive athletes and impaired glucose tolerance (IGT) or impaired fasting 
glucose (IFG) at screening visit. 
Subjects showing a strong loss in weight (defined as more than 5% loss of body weight 
during run-in) and changes in or onset of pharmacological treatment, especially the use of 
antibiotics due to infectious diseases, during run in phase were excluded from the study. 
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Anthropometric parameters 
Body weight, body height, waist circumference and blood pressure were measured by 
standard operating procedures (SOP) Version 1.1, 2009 of the German Diabetes Center 
at each visit. In brief, body height and body weight were measured in standing position, 
feet next to each other, using calibrated Seca®-scales (Hoff Waagen, Essen, Germany) 
with light clothing, without shoes. Waist circumferences were measured with nonflexible 
tape. The tape horizontally surrounded the subjects body between proximal costal arch 
and distal iliac crest. The subjects were instructed to stand with their feet pointing 
forwards and approximately 25-30cm apart and to breathe out gently while the 
measurement was taken. Measurements were recorded in centimetres and as two 
independent measurements on each subject, and should not differ by more than 0.2 cm to 
ensure reproducibility. Blood pressure and pulse were measured using digital Omron M4-
1® (Omron® Helathcare Europe B.V., Hoofdorp, The Netherlands) after removing 
restrictive clothing from the arm and on participant’s heart level with the palm of the hand 
facing upwards, while the subject was sitting in a comfortable, calm position.  
Bioelectrical impedance analysis (BIA, Nutriguard-S, Data Input GmbH Darmstadt, 
Germany, software Nurti 3 Version 3.0.88, P&P Trendmedia GmbH, Stockdorf, Germany) 
was used to measure body composition during study. BIA-measurements were performed 
in duplicates on each subject to ensure reproducibility and to calculate lean body mass 
and fat mass according to Segal (Segal et al., 1988). 
 
Intestinal permeability in vivo 
Alterations of the integrity of the intestinal barrier are involved in the pathogenesis of many 
diseases, e.g. inflammatory bowel diseases (IBD) and allergic intolerances to nutrients. In 
animal models a link between increased plasma endotoxin levels, released from the gut 
microbiota as a consequence of increased intestinal permeability, and obesity and insulin 
resistance has been described. Intestinal permeability might be the interface of the 
commensal microorganisms and endotoxins on one hand and the mucosal immune 
system on the other hand which need to balance between tolerance and immune 
response in the core of metabolic dysfunctions (Vajro et al., 2013; Scaldaferri et al., 2012; 
Teixeira et al., 2012). 
Intestinal permeability is measured as the ability of two non-metabolized sugar molecules 
- mannitol and lactulose - to permeate the intestinal mucosa. Mannitol is easily absorbed 
and serves as a marker of transcellular uptake, while lactulose is only slowly absorbed 
and serves as a marker for mucosal integrity. To perform the test, lactulose and mannitol 
at defined amounts are mixed and ingested. The test measures the amount of lactulose 
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and mannitol recovered in a urine sample over the following 6 hours after intake. Initially, 
we attempted to measure gut barrier function by the before mentioned Lactulose-
Mannitol-Test (Dastych et al., 2008; Bosi et al., 2006). However, we found a wide range of 
individual variation (>14%). Thus, our focus returned to serum parameters to measure gut 
barrier function, e.g. zonulin. The serum levels of the protein zonulin, which is a modulator 
of the intestinal permeability, are positively correlated with intestinal permeability and are 
detectable in peripheral blood (Sapone et al., 2006). Samples to determine zonulin 
concentrations were collected before (week 4) and after intervention (week 8). In 
cooperation with Prof. Alessio Fasano (Director of Mucosal Biology Research Center, 
University of Maryland School of Medicine, Baltimore, MD, USA), we aimed to use a 
newly validated human monoclonal antibody-based ELISA to measure serum zonulin 
concentrations. However, a thoroughly evaluated and validated assay has not yet been 
fully established with the end of this study (A. Fasano, personal communication). 
 
Gastric emptying  
Data of 13C-octanoic acid breath test were used to assess disturbed gastric emptying and 
potentially exclude patients with pathologically delayed gastric emptying as there is a 
reciprocal interplay of gut hormones GLP-1 and GLP-2 and gastric motility (Meier et al., 
2006; Guan et al., 2012; Wettergren et al., 1993; Nauck et al., 1997). Therefore, at the 
end of the run-in phase, each subject underwent a 13C-octanoic acid breath test, which is 
well established at our institute (Ziegler et al., 1996). In brief, breath testing was 
performed after 12 h overnight fast and consisted of scrambled egg, white bread (60 g), 
margarine (5 g) and 150 ml water (total kcal 250). The tracer (100 mg 13C-octanoic acid, 
euriso-top®, Saint-Aubin Cedex, France) was given in the egg yolk. Before, immediate 
after the test meal and in time intervals of 15 min, a breath sample of 13CO2 recovery was 
taken and measured by infrared isotope analyser (IRIS, Wagner GmbH, Bremen, 
Germany). 
The rationale of 13C-octanoic acid breath test (13C-OBT) is to measure gastric emptying of 
solids based on (1) the retention of 13C-octanoic acid in the solid phase of a standard test 
meal during its passage through the gastric environment, followed by (2) a rapid 
disintegration from the solid phase in the duodenum with (3) subsequent absorption of 
13C-octanoic acid, and (4) hepatic oxidation to 13CO2 (Braden et al., 2006). 
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Fig. 6 Gastric emptying rate 
Normal gastric emptying rate of one participant, 
exemplarily. Every dot represents one measurement of 
13CO2 recovery in the breath after oral administration of a 
13C-octanoic acid test meal. The half time of exhaled 
13CO2 is 48 min and represents a normal gastric 
emptying. 
 
In vitro validation studies have shown that in a gastric environment 13C-octanoic acid is 
firmly retained in the yolk of scrambled egg used as test meal. Once the meal reaches the 
duodenal lumen, 13C-octanoic acid is rapidly absorbed through the intestinal mucosa and 
oxidized to 13CO2 in the liver. The appearance of 13CO2 in breath after oral administration 
of 13C-octanoic depends mainly on the gastric emptying of the egg yolk into the duodenum 
(rate limiting step, figure 6). The other metabolic steps (absorption and oxidation) do not 
influence the rate of 13CO2 exhalation as shown by studies in which, after duodenal 
instillation of 13C-octanoic acid, 13CO2 appears in breath almost immediately with very little 
inter-subject variability (Perri et al., 2005). 
 
Analysis of the faecal content 
Compliance for taking Lactobacillus (L.) reuteri containing capsules was assessed by 
screening for the bacteria in faecal samples. For the species-specific quantification, real-
time PCR to detect total bacterial load (Euba) (Yang et al., 2002), enterobacteriaceae 
content (tuf), Lactobacillus spp. (Lac. spp.) (Byun et al., 2004), and L. reuteri (Haarman 
and Knol, 2006) was performed. The real-time PCR was established in cooperation with 
Prof. Birgit Henrich at the Institute of Medical Microbiology and Hospital Hygiene at the 
Heinrich-Heine-University.  
In brief, faecal samples were processed within 24 hours after collection and stored at -20° 
C until further analysis. DNA extraction was performed using a BioRobot EZ1 machine 
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions (Bizhang et al., 
time 1/2
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2011). All primers and probes used for species-specific real-time PCR were retrieved from 
the literature or configured via the Primer Express software (DNASTAR, Madison, WI, 
USA, table 2), and qPCR Mastermix No ROX, Cat.-No: RT-QP2X-03NR (Eurogentec, 
Seraing, Belgium) was used. PCR components were added to an end-volume of 25 µl per 
reaction mixture. Amplification of the DNA was carried out on CFX Cycler (Version 
1.5.534.0511; BioRad, Munich, Germany), with the following cycling scheme: 50°C for 2 
min and 95°C for 10 min, followed by 45 cycles of 95°C for 15 s and 60°C for 1 min.  
To reduce the risk of contamination during the analyses, dedicated rooms, dedicated 
equipment, and sterile water (delta select, Dreieich, Germany) were used. To exclude a 
possible cross-reaction of the L. reuteri real-time PCR with DNA from other bacteria of 
fecal samples, we tested potential pathogens of fecal samples (E. coli, S. saprophyticus, 
C. perfringens, H. pylori, P. aeruginosa, S. aureus, Campylobacter spp.) in a 
concentration of 106 copies. None of the tested pathogens showed cross-reactivity or 
inhibition with the L. reuteri real-time PCR.  
 
Table 2 Primer and Probes 
Genus / 
Species 
Primer / Probe Sequence (5'-3') Ampl. Ampl. Lit. 
Total bacterial 
load (Euba) 
P 891 F TGG AGC ATG TGG TTT AAT TCG A 22 nt 
159 bp 
(Yang et 
al., 2002) 
 
P 1033 R TGC GGG ACT TAA CCC AAC A 19 nt 
P 1024 02 S CAC GAG CTG ACG ACA RCC ATG CA 23 nt 
Escherichia 
coli (tuf) 
tuf-F TGG TCA GGT ACT GGC TAA GC 20 nt 
78 bp 
configured 
via the 
primer 
express 
tuf-R TCT TTG GAC AGA ATG TAC ACT TCA 24 nt 
tuf-S CCA TCA AGC CGC ACA CCA AGT TCG 24 nt 
Lactobacillus 
spp (Lac. spp) 
Lacto-F2 TGG AAA CAG ATG CTA ATA CCG 21 nt 
235 bp 
(Byun et 
al., 2004) 
Lacto-R2 CGT CCA TTG TGG TAG ATT CCC T 22 nt 
Lacto-S CTG AGA CAC GGC CCA WAC TCC TAC GG 26 nt 
L. reuteri 
F_reut_IS ACC GAG AAC AAC GCG TTA TTT 21 nt 
95 bp 
(Haarman 
and Knol, 
2006) 
 
R_reut_IS CAT AAC TTA ACC TAA ACA ATC AAA GAT TGT 30 nt 
P_reut_IS ATC GCT AAC TCA ATT AAT 18 nt 
Primers and Probes were synthesized by Metabion (Martinsried, Germany) 
 
To quantify the bacterial DNA load of each sample, we generated PCR-standards with 
distinct DNA-copies. We used pCR 2.1TOPO-Vektor (3,931kb, Invitrogen, Carlsbad, CA, 
USA) to clone the species-specific amplicons of each real-time PCR. After transformation 
of competent E. coli, plasmid-containing E. coli clones were grown on LB-Amp plates. 
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Plasmid-DNA of positive clones was prepared by using the High Pure Plasmid Isolation 
Kit (Roche Diagnostics, Mannheim, Germany), and as a control of insert length digested 
with using the restriction enzymes Xho I und Hind III (Fermentas, St. Leon-Rot, Germany). 
A mixture of 10 µl restriction mix and 2 µl of sample-buffer were separated on 2% agarose 
gel to determine the length of the inserted fragments. Clones with the anticipated insert 
length (table 2) were used for preparation of standards containing 105 - 10 copies of 
plasmid, for quantification.  
In preliminary experiments we found that the genus-specific Lac. spp PCR and the 
species-specific L. reuteri PCR were not comparable due to the different lengths of the 
resulting amplicons. Therefore, we decided to recalculate the pathogenic load of the 
samples. We recalculated the standards of L. reuteri, by using genomic DNA of L. reuteri 
in two dilutions, of which the genome equivalents were estimated in Lac. spp qPCR. 
 
Oral glucose tolerance test (OGTT)  
The oral glucose tolerance test (OGTT) was performed in the morning after an overnight 
fast with 75 g glucose ad 300 ml water (Dextrose O.G-T., Roche Diagnostics Deutschland 
GmbH, Mannheim, Germany). In blood samples drawn at different time points during the 
OGTT we measured the concentrations of blood glucose, insulin, C-peptide, glucagon, 
GLP-1, GLP-2, GIP, HbA1c, FFA, TG, immune mediators and reactive oxygen species 
(ROS, figure 7, table 3) to determine the metabolic status of subjects. 
 
 
Fig. 7 Schematic representation of the oral glucose tolerance test (OGTT).  
Collection of two fasting blood samples was followed by immediate ingestion of 
glucose solution, containing 75 g glucose diluted in 300 ml water followed directly. 
Every black dot represents a time point for blood sampling. Investigated parameters 
from blood samples were concentrations of blood glucose, insulin, C-peptide, 
glucagon, GLP-1, GLP-2, GIP, HbA1c, free fatty acids, triglycerides, immune 
mediators, reactive oxygen species.  
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The parameters obtained from the OGTT also allow calculation of the oral glucose insulin 
sensitivity index (OGIS). The index is a validated method for the assessment of insulin 
sensitivity from the 3-hour oral glucose tolerance test with 75 g glucose. The OGIS 
provides information analogous to the index of insulin sensitivity (M-Value) obtained from 
the gold standard, the hyperinsulinemic-euglycemic clamp (Mari et al., 2001; Mari et al., 
2005), which is described in a separate chapter (page 32).  
 
Assessment of insulin secretion and β-cell function 
Insulin secretion as a measure of β-cell function can be investigated by several metabolic 
tests. From measurements of plasma glucose, insulin, and C-peptide concentrations 
during the OGTT, β-cell function can be calculated. In cooperation with Prof. Giovanni 
Pacini, Padova, Italy we aimed to test β-cell activity by determining the disposition index 
(DI) (Kahn et al., 1993), area under the curve (AUC) insulin, and AUC glucose during the 
OGTT (Mari et al., 2001; Faerch et al., 2008; Thomaseth et al., 1996).  
Moreover, β-cell function is assessable by the insulinogenic index (Mari et al., 2001; Mari 
et al., 2005). The interplay between insulin sensitivity and secretion can be described as 
the β-cells adaptive response to changes in insulin resistance (Ahren and Pacini, 2004). 
This interplay can be determined by the products OGIS × AUCCP and OGIS × AUCINS, 
where the AUCs are defined as the area under the concentration curves of C-peptide and 
insulin, respectively. These indices, called adaptation (AI) and disposition (DI) index were 
originally developed for the intravenous (i.v.) glucose test but have been proven to be 
useful determinants for the calculation of β-cell function from OGTT (Ahren and Pacini, 
1997; Kahn et al., 1993; Pacini, 2006). Additonally, the DI was described as one of the 
most accurate physiologic parameters for the detection of changes of β-cell activity in the 
whole organism (Bergman et al., 2002).  
 
Isoglycemic glucose infusion test 
The rationale for performing the isoglycemic glucose infusion test is to measure the 
incretin effect (Nauck et al., 2004). The incretin effect is defined as the phenomenon that 
oral glucose administration induces a much higher degree of insulin secretion compared 
to a parenteral isoglycemic i.v. glucose infusion. This effect is caused by the release of 
incretins in response to the oral uptake of glucose (figure 8) (Drucker, 2006; Drucker and 
Nauck, 2006; ELRICK et al., 1964).  
The isoglycemic glucose infusion test was newly established at the Clinical Research 
Center of the Institute for Clinical Diabetology at the German Diabetes Center.  
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Two catheters (Vasofix, Braun, Melsungen, Germany) were inserted into antecubital veins 
in the left and right arm for blood sampling and infusions, respectively. The test was 
performed in the morning after a 10 hours overnight fast. After drawing basal blood 
samples at -120, -15, -5 and 0 min, the test was started by an isoglycemic intravenous 
glucose infusion (20% in sterile water enriched with 2% [6,6-2H2]glucose) over 3 hours, 
using an Infusomat® Space (Braun, Melsungen, Germany). The glucose infusion rate was 
adjusted to the interpolated blood glucose concentrations achieved during OGTT. 
Samples for blood glucose measurements were drawn every 2 min during isoglycemic 
intravenous glucose infusion test. The hyperinsulinemic-euglycemic clamp followed 
directly thereafter (figure 9).  
To assess the incretin effect we calculated the AUC of insulin, C-peptide, glucagon, GLP-
1, GLP-2 and GIP at each visit and compared the difference of ΔAUC before (week 4) 
versus ΔAUC after (week 8) intervention in the subjects of the verum and the placebo 
group, for each parameter (insulin, C-peptide, glucagon, GLP-1, GLP-2 and GIP, 
respectively). ΔAUC was defined as AUC of OGTT minus AUC of isoglycemic intravenous 
glucose infusion test. Missing values of insulin, C-peptide, GLP-1, GLP-2 and GIP at -15 
min were replaced by values determined at 0 min and vice versa. Missing values during 
the time course were interpolated, and at 180 min extrapolated, by calculation of the mean 
in regard to the time-interval of the missing value. For GLP-1 (14 out of 756 values), GLP-
2 (14 out of 756 values), glucagon (2 out of 420 values) and for GIP (14 out of 756 values) 
were calculated by interpolation or extrapolation. 
 
 
 
Fig. 8 The biological incretin effect determined by the isoglycemic clamp technique 
Exemplarily, the blood glucose curve during OGTT (green) and isoglycemic i.v. glucose infusion 
(orange, left diagram) and the corresponding serum insulin levels (right diagram) of one 
participant. The area under the curve (AUC) of insulin determined during OGTT (green) minus the 
AUC of insulin determined during isoglycemic intravenous glucose infusion test (orange) indicate 
the incretin effect (black arrow).  
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Hyperinsulinemic-euglycemic clamp with isotopic dilution to assess insulin sensitivity 
The gold standard to determine insulin sensitivity is the hyperinsulinemic-euglycemic 
clamp test. Combined with tracer substances this test allows to differentiate between 
hepatic and peripheral (muscle) insulin resistance. Moreover, the hyperinsulinemic-
euglycemic clamp test allows to quantify the severity of insulin resistance (Defronzo et al., 
1979). However, this method is difficult to implement in daily clinical practice. Therefore, 
several indices based on data from the oral glucose tolerance test and/or fasting blood 
sampling have been developed to assess insulin sensitivity (Armato et al., 2012; Matsuda 
and Defronzo, 1999; Anderwald et al., 2007). For example, the oral glucose insulin 
sensitivity index (OGIS) provides information of insulin-mediated glucose clearance, 
calculated from plasma glucose, insulin, and C-peptide concentrations during the oral 
glucose tolerance test (OGTT). The OGIS has been validated against the 
hyperinsulinemic-euglycemic clamp test and the results of the two methods show a high 
correlation (Mari et al., 2001; Mari et al., 2005; Ahren and Pacini, 2004). To reduce these 
cumbersome experimental clinical settings, further indices to determine insulin resistance 
have been established based on mathematical methods e.g. HOMA (homeostatic model 
assessment) (Wallace et al., 2004; Wallace and Matthews, 2002; Matthews et al., 1985; 
Mojiminiyi and Abdella, 2010; Levy et al., 1998; Geloneze et al., 2009) and QUICKI 
(quantitative insulin sensitivity check index) (Katz et al., 2000; Hrebicek et al., 2002; Chen 
et al., 2003). 
In this clinical trial the gold standard hyperinsulinemic-euglycemic clamp test combined 
with isotopic dilution (6,6[2H2]glucose) was used to assess whole body and hepatic insulin 
sensitivity. In brief, after baseline blood sampling at -120 min, a primed (0.36 mg*(fasting 
blood glucose (mg/dl)/90 mg/dl)*body weight (kg)-1* min-1 for 5 min), followed by a 
constant intravenous infusion (0.036 mg * body weight (kg)-1 * min-1) of the [6,6-
2H2]glucose over two hours for assessment of endogenous glucose production (EGP) was 
given (figure 9). Directly after the isoglycemic glucose infusion test (180 min), a priming 
dose of short-acting human insulin (Insuman® Rapid, Sanofi-Aventis, Frankfurt, Germany) 
for 10 min was infused followed by a constant insulin infusion (40 mU/m2 body surface 
area) over two hours, using Perfusor® Space (Braun, Melsungen, Germany). During this 
time blood glucose was adjusted to 80 mg/dl by a variable infusion rate of a 20% glucose 
solution, enriched with 2% [6,6-2H2]glucose to maintain the blood glucose concentration 
during the clamp test according to the HOTGINF protocol (Weickert et al., 2007; Nowotny 
et al., 2013). Throughout the hyperinsulinemic-euglycemic clamp blood samples were 
collected in 5 min intervals for the measurement of whole blood glucose concentration in 
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duplicates. The glucose infusion rates during the last 30 minutes of the clamp were used 
to calculate whole body insulin sensitivity (figure 9). Rates of EGP were determined from 
the tracer infusion rate of [6,6-2H2]glucose and its enrichment to the hydrogens bound to 
carbon 6 divided by the mean percent enrichment of plasma [6,6-2H2]glucose. Steady-
state equations were appropriate for calculation of basal EGP and insulin-suppressed 
EGP during the last 30 min of clamp. 
 
 
Fig. 9 Schematic representation of the time course of the clamp studies 
Every black dot represents a time point for taking a blood sample. Investigated parameters from 
blood were blood glucose, insulin, C-Peptide, GLP-2, GLP-1, GIP, HbA1c, free fatty acids 
(FFA), triglycerides (TG), immune mediators, reactive oxygen species (ROS), atom percent 
enrichment of [6,62H2] glucose (APEs) 
 
 
Gas chromatography-mass spectrometry to determine atom percent enrichment of 
[6,62H2] glucose 
The atom percent enrichment (APE) of 2H was determined by established methods 
according to standard operating procedures (SOP) of the gas chromatography-mass 
spectrometry (GC-MS) and hormone analytical laboratory at the German Diabetes Center 
headed by Ing. Peter Nowotny. After deproteinization, determination of APE of 2H was 
done as described before (Krebs et al., 2001; Nowotny et al., 2013). In brief, 100 µl KF-
EDTA plasma was diluted with an equal amount of water and deproteinized after adding 
300 µl of 0,3 N ZnSO4 solution followed by the addition of 300 µl of 0,3 N Ba(OH)2 
solution. After vortexing for 20 minutes, samples were centrifuged at 21.000 g at room 
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temperature. Thereafter, 400 µl of the sample were evaporated under a stream of nitrogen 
5.0 at 37°C and both endogenous glucose and infused [6,6-2H2]glucose were derivatized 
with HOX (100 µl of 2% solution in pyridine, 60 min at 90°C, cooling for 5 min) and acetic 
anhydrate (200 µl, 60 min at 90°C, cooling for 5 min) to the aldonitrile-pentaacetate. The 
analyses were performed on a Hewlett-Packard 6890 gas chromatograph equipped with a 
25 m/0.25 mm/0.12 µm CPSil5CB capillary column (Chrompack/Varian, Middelburg, 
Netherlands) and interfaced to a Hewlett Packard 5975 mass selective detector. Intra- and 
inter-assay variations were 0.6% and 1.0%.  
 
Indirect calorimetry  
The indirect calorimetry is a non-invasive method to determine in vivo the whole body 
energy expenditure and substrate oxidation by measuring the oxygen consumption (VO2) 
and the carbon dioxide production (VCO2) to calculate the respiratory quotient (RQ = 
VCO2/VO2) and resting energy expenditure (REE = (3.941*VO2+1.11*VCO2)*1.44) 
according to the abbreviated Weir equation.  
Substrate oxidation was calculated according to Frayn (Frayn, 1983) with a fixed 
estimated protein oxidation rate (Pox) of 15% of REE: carbohydrate oxidation rate (mg/kg 
body weight*min) = [(4.55*VCO2) – (3.21*VO2) – 0.459*Pox]*1000/kg bodyweight; where 
VCO2 is carbon dioxide production and VO2 is oxygen consumption; and lipid oxidation 
rate (mg/kg body weight*min) = [(1.67*VO2) – (1.67*VCO2) – 0.307*Pox]*1000/kg 
bodyweight. Non-oxidative glucose disposal was calculated as Rd (rate of glucose 
disappearance, mg/kg body weight*min) minus carbohydrate oxidation (Nowotny et al., 
2013). Due to an inherent variability of the instrumentation, case-related in vitro validation 
by individual calibration control evaluation (ICcE) was necessary. The in vivo rates were 
calculated, thereafter gaseous CO2 and N2 were infused into the hose of the metabolic 
cart and the mass-flow meters adjusted until the mean rates, observed in an individual 
subject, were exactly met. The resulting adjustment of the mass-flow regulator (in L/min, 
standard conditions, T=273°K, p=1013 hPa) was then taken to calculate the estimate for 
the true breath gas exchange rate of the subject (Schadewaldt et al., 2013).  
Indirect calorimetry using canopy mode was performed using Vmax Encore 29n 
(CareFusion, Höchberg, Germany) at baseline and during steady state conditions of 
hyperinsulinemic-euglycemic clamp over a period of 20 min after 10 min adaptation time 
to the setting.  
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Biochemical analysis 
The laboratory parameters, like blood cell count, HbA1c, triglycerides (TG), cholesterol, 
HDL-cholesterol, LDL-cholesterol and CRP, were determined by established methods 
according to SOPs of the gas chromatography-mass spectrometry (GC-MS) und hormone 
analytical laboratory at the German Diabetes Center.  
 
 
Table 3 Blood sampling protocol of OGTT 
tube and stabilizer chilled color of tube [n] [ml] -15 0 10 20 30 60 90 120 150 180 ml
blood count K-EDTA / / 1 1 X 1
HbA1c K-EDTA / / 1 2 X 2
blood glucose VB Lsg. (EKF) / / 10 1.5 (0.5+1) X X X X X X X X X X 15
insulin, C-peptide, cortisol Serum             RT blue 10 3.5 X X X X X X X X X X 35
total FFA , TG , cholesterol Na-EDTA + Orlistat ICE green 10 2 (2x1ml) X X X X X X X X X X 20
glucagon Na-Hep + Aprotinin  ICE red 5 2.5 X X X X X 13
GLP-1, GIP DPP IV      ICE purple 9 3 X X X X X X X X X 27
GLP-2 DPP IV                        ICE purple 5 6 (2x3ml) X X X X X 30
immune mediators and CRP Serum             RT white 2 1.75/3.5 X X 5,3
adiponectin, leptin Serum             RT yellow 1 1.75 X 1,8
retain sample EDTA              RT / 1 3 X 3
total (ml) 153
tubes (n) 5 6 2 2 2 4 2 4 1 5 33
tubes (ml) 15,5 19 6,5 6,5 6,5 12,5 6,5 13 3,5 16 105
syringe (ml) 3,5 6 3,5 6 3,5 6 3,5 6 3,5 6 48
instantly measure
instantly measure
blood collection scheme
Room temperature (RT), free fatty acids (FFA), triglycerides (TG), glucose-dependent insulinotropic 
polypeptide (GIP), glucagon-like peptide-(GLP)-1 and GLP-2, C-reactive protein (CRP), dipeptidyl 
peptidase-4 (DPP-4), stabilizer for FFA 40µl Orlistat and 20µl Na-EDTA, for glucagon 40µl Aprotinin and 
20µl Na-Heparin  
 
Briefly, fresh drawn blood samples were immediately chilled, centrifuged after 10 min and 
supernatants stored at -20°C until further analysis. Insulin, C-peptide, total free fatty acids 
(FFA) and glucagon were determined from venous drawn blood at baseline, during 
several time points of the 3 hours OGTT (table 3) and the hyperinsulinemic-euglycemic 
clamp test. The blood sampling protocols for OGTT and hyperinsulinemic-euglycemic 
clamp test was used initially for 3 pilot participants of each group. After verification of time 
points for blood sampling the scheme was adjusted (table 3).  
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Serum insulin was measured by a microparticle enzyme immunoassay (MEIA) on an 
AXSYM analyzer (Abbott, Abbott Park, IL, USA), C-peptide was measured by 
chemiluminescence immunoassay on an Immulite1000 system (Siemens, Erlangen, 
Germany) and plasma glucagon was analyzed by radio immune assay (RIA, Millipore, St. 
Charles, MO, USA). Plasma FFA concentrations were determined with the 
microfluorimetric method (Wako, Neuss, Germany) and cortisol was measured using a 
fluorescence polarization immunoassay on an Axsym analyzer (Abbott). 
Venous whole blood glucose was measured in duplicate by Biosens C_line, GP (EKF 
diagnostic GmbH, Barleben, Germany) based on an electrochemical method using a chip-
sensor technology (Nowotny et al., 2012). In brief, the β-D-Glucose in the samples was 
enzymatically cleaved in gluconic acid and hydrogen peroxide. The electrode measured 
the concentration of the hydrogen peroxide. 
 
Incretin concentrations  
Samples of peripheral blood for the determination of GLP-1, GLP-2, and GIP 
concentrations were collected into DPP-4-inhibitor containing tubes (BD P700, BD 
Biosciences, Franklin Lakes, NJ, USA) during OGTT and isoglycemic glucose infusion 
test. Measurements of all three gut hormones were performed in cooperation with the gas 
chromatography-mass spectrometry (GC-MS) und hormone analytic laboratory at the 
German Diabetes Center.  
Concentrations of the gut hormone GIP were determined by using a gut hormone panel 
according to the manufacturer’s instructions (human GIP (total) ELISA, Millipore, St. 
Charles, USA, CV 12%).  
At first, concentrations of gut hormones GLP-1 and GLP-2 were determined by using a gut 
hormone panel according the manufacturer instructions (GLP-1 ELISA, TECOmedical, 
Sissach, Switzerland, CV 10%; GLP-2 ELISA, Uscn Life Science Inc., Wuhan, China, CV 
15%, respectively). The manufacture instructions for GLP-2 measurements were changed 
by the company during the study period, requiring the use of other blood collection tubes 
and titration procedures. The required sample volume of EDTA plasma was not available, 
because we collected the blood into DPP-4-inhibitor containing tubes (BD P700, BD 
Biosciences, Franklin Lakes, USA). Additionally, the assay showed broad variance.  
 
In a second step, we got the opportunity to get GLP-1 and GLP-2 measured by a well 
accepted and widely used method, as a part of a scientific collaboration with Prof J.J. 
Holst from the Novo Nordisk Foundation Center for Basic Metabolic Research, University 
of Copenhagen. The gut hormones GLP-1 and GLP-2 were measured as previously 
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described (Orskov et al., 1994; Hartmann et al., 2000; Deacon and Holst, 2009). In brief, 
GLP-1 and GLP-2 concentrations in plasma were measured by radioimmunoassays (RIA) 
after extraction of plasma with 70 % and 75% ethanol (vol/vol, final concentration), 
respectively. Carboxy-terminal GLP-1 immunoreactivity was determined using antiserum 
code no. 89390 which has an absolute requirement for the intact amidated carboxy-
terminus of GLP-1 (7-36amide) and crossreacts less than 0.01% with carboxy-terminally 
truncated fragments and 89% with GLP-1 (9-36amide). GLP-2 was measured with an N-
terminal specific antiserum, detecting only fully processed GLP-2 of intestinal origin. As 
standard, we used synthetic human GLP-2 and the tracer was rat GLP-2 with an Asp33 -> 
Tyr33 substitution. Sensitivity for both assays was below 5 pmol/l, and intraassay 
coefficient of variation below 10 %. 
 
 
Fig. 10 Correlation of the GLP-1 concentrations detected by two different methods 
Shown are the log GLP-1 values measured by ELISA (x-axis) and measured by RIA (y-axis), 
exemplarily at Visit 6. The log transformed GLP-1 values exhibit a linear relationship 
(r=0.778, p<0.0001). Regression Equation: log GLP-1 RIA = 2.23 + 0.60 * log GLP-1 ELISA. 
 
 
Statistical analysis of the GLP-1 values, detected by the two different methods, showed a 
high correlation (r=0.778, p<0.0001, figure 10). In comparison, the log-transformed GLP-1 
values, measured by the new radioimmunoassay (RIA) showed a smaller standard 
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deviation than the ELISA values (logGLP-1 ELISA CV 1.39, logGLP-1 RIA CV 0.94, 
respectively).  
 
Reactive oxygen species (ROS)  
Thiobarbituric acid-reactive substances (TBARS) measured from serum samples, reflect 
concentrations of oxidized lipids as markers of oxidative stress (Ristow et al., 2009). 
Measurements of TBARS were performed in cooperation with Dr. Gilles Séquaris of the 
research group energy metabolism of the Institute for Clinical Diabetology at the German 
Diabetes Center. Briefly, 50 µl serum were diluted in 50 µl 1.15% KCl solution and mixed 
with 0.8% thiobarbituric acid and 8.1% sulfosalicylic acid before TBARS extraction by 
butanol/pyridine (15:1). After separation of the butanol/pyridine layer by centrifugation 
(3000 g, 20 min, room temperature), the TBARS content (pmol/mg) was assayed on a 
Flx800 fluorometer (BioTek, Bad Friedrichshall, Germany).  
 
Immune mediators and adipokines 
Concentrations of pro-inflammatory (interleukin (IL)-6, IL-8, IL-1β, interferon-gamma (IFN-
γ), tumor necrosis factor (TNF)-α, monocyte chemotactic protein (MCP)-1, macrophage 
inflammatory protein (MIP)-1β) and regulatory (IL-10, IL1ra) systemic cytokines and 
chemokines were determined by using a Flurokine MAP multiplex kit, human cytokine 
panel A (R&D Systems, Minneapolis, MN, USA) and quantified with Luminex technology 
(Bio-Rad Bioplex, Nazareth, Belgium) (Pfleger et al., 2008b; Pham et al., 2011). The 
adipokines leptin and adiponectin were determined by using the Flurokine MAP kit human 
obesity panel (R&D Systems, Minneapolis, USA) and measured by Luminex technology 
(Bio-Rad Bioplex, Nazareth, Belgium) as well (Pham et al., 2013). Following the 
manufacturer’s instructions, color-coded microparticles with pre-coated analyte-specific 
antibodies were used to bind the analytes of interest. Detection of analytes was done by a 
microparticle-specific laser of the Bio-Plex-System, another laser determined the amount 
of analyte bound, because it measured the magnitude of the signal, which is in direct 
proportion. Standard curve and three control samples of two different dilutions were 
assayed in duplicates on all plates. All samples of one subject were measured together on 
one plate and in a combination of lean and obese subjects receiving verum or placebo. 
The mean intra- and inter-assay variance (CV) for all nine cytokines as well as for 
adiponectin and leptin was <15%. Detection limits were IL-6 0.50 pg/ml, IFN-γ 0.39 pg/ml, 
IL-8 0.42 pg/ml, TNF-α 0.61 pg/ml, IL-1β 0.34 pg/ml, MCP-1 0.11 pg/ml, MIP-1β 4.32 
pg/ml and IL-10 0.38 pg/ml, IL1ra 1.6 pg/ml, adiponectin 124.28 pg/ml and leptin 81.58 
pg/ml. 
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Limulus test to measure LPS 
Serum endotoxin levels are a validated parameter to access gut permeability and 
inflammatory status (Cani et al., 2008a). Measurements of endotoxin were performed in 
cooperation with the research group immune modulation of the Institute for Clinical 
Diabetology at the German Diabetes Center headed by Priv.-Doz. Dr. Volker Burkard. 
Serum endotoxin (lipopolysaccharide, LPS) content was determined by the use of a 
chromogenic limulus amebocyte lysate (LAL) assay (QCL-1000 Lonza Ltd., Verviers, 
Belgium) according to the manufacturer’s instructions with slight modifications (Habich et 
al., 2005). In brief, samples were centrifuged and diluted with pyrogen free water and 
heated for 15 minutes at 75°C. After pre-incubation of the plate for 10 minutes at 37 ± 
1°C, all reagents, water blank, endotoxin standards, samples, and positive controls were 
carefully dispensed into the appropriate wells of the microplate and gently mixed before 
incubation. The reaction was stopped by the addition of 30% acetic acid and the extinction 
was measured by 405 nm photometrically on an ELISA-Reader Synergy 2 Gen5™ CL 
(BioTek, Bad Friedrichshall, Germany). 
 
1H MRS for the determination of hepatic and muscular fat content  
All magnetic resonance imaging (MRI) and spectroscopy (MRS) were determined by 
established methods according to standard operating procedures (SOP) of the junior 
research group Metabolic Imaging headed by Dr. Jong-Hee Hwang at the Institute for 
Clinical Diabetology at the German Diabetes Center. All MRS measurements were 
performed on a 3.0 Tesla whole body clinical scanner (Philips Healthcare, Achieva, X-
series, Best, The Netherlands) at DDZ. The quantification of liver and myocellular 
triglyceride content from 1H-MR spectroscopy (MRS) was assessed relative to the internal 
water, and calculated as described previously (Krssak et al., 2004b; Krssak et al., 1999; 
Hwang et al., 2007; Krssak et al., 2010; Hamilton et al., 2011). The percentage of fat 
content was quantified as fat signals relative to the internal water peak at 4.7 ppm. The 
lipid peaks at -(CH2)n - (1.3 ppm) and methyl -(CH3) (0.9 ppm) were integrated by NUTS 
software (Acorn NMR, Livermore, CA, US).  
 
Measurement of hepatocellular lipid content (HCL) by 1H MR spectroscopy 
Using a fast spin echo sequence, MR images around the liver were obtained by using a 
navigation echo to remove breathing motion artifacts. To localize an appropriate voxel in 
the liver, transverse and coronal T2-weighted (T2w) images of 7 mm thickness were 
acquired. A Position Resolved Spectroscopy (PRESS) sequence with a repetition time of 
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4 s and an echo time of 35 ms was employed. Spectroscopic data was acquired in a 
volume of interest (VOI) of 25 x 25 x 25 mm3 in the liver. The VOI were carefully placed to 
avoid major vessels and fat depots in the liver. Data was transferred to a desk computer 
and processed using NUTS software (Acorn NMR, Livermore, CA, USA).  
 
Determination of intramyocellular lipid content (IMCL) by 1H MR spectroscopy  
MR images of the left calf were acquired using a fast spin echo sequence. To choose a 
voxel in the soleus and tibialis anterior muscles, transverse, coronal and sagittal T1-
weighted (T1w) images of 4 mm slice thickness were acquired to clearly visualize fat 
depots. Again, a VOI was carefully placed to avoid muscular fat depots. A PRESS 
sequence with a repetition time of 2 s and an echo time of 31 ms was used. Spectral data 
was acquired with and without water suppression (CHESS) for a VOI of 12 x 12 x 12 mm³. 
Spectra were processed to assess contents of IMCL using jMRUI (Java-based Magnetic 
Resonance User Interface, EU Human Capital and Mobility Networks, France) software. 
 
Lactobacillus reuteri capsules and placebo capsules 
Lactobacillus reuteri was encapsuled by Nutraceutix (Nutraceutix, Inc. Redmond, WA, 
USA). Nutraceutix has a patented technology to encapsulate probiotics with a protective 
layer, to protect probiotics from gastric acid, while providing an optimal release throughout 
the intestine (BIO-tract® tablets). Probiotics and placebos were produced in optically 
identical capsules. Packaging and organoleptic appearance was identical, too. All 
capsules were generously provided by Nutraceutix (Nutraceutix, Inc. Redmond, WA, 
USA). Each participant received the capsules in the corresponding bottle allocated by an 
independent researcher with no further involvement in this clinical trial, assigned 
according to the randomization list. The appropriate package was handed to the particular 
participant.  
 
Statistical data analysis and power calculation  
Statistical data analysis and the power calculation were performed in cooperation with Dr. 
Klaus Strassburger of the Department of Biometry and Epidemiology at the German 
Diabetes Center. 
 
Power calculation 
As no relevant data preexisted from probiotic studies reporting changes of incretins, 
particularly of GLP-1 concentration, we assumed data from studies with prebiotics and 
used this as a basis for power calculation. Group size was calculated in order to detect a 
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mean difference of one SD before versus after intervention, with a probability (power) of at 
least 80%. Mean differences between verum and placebo of at least 1.33 SD can be 
detected with a power of 80%.  
 
Statistical data analysis 
SAS for Windows Version 9.2 (SAS Institute, Cary, NC, USA) was used for all analyses. 
Data are presented as means and standard deviations (mean ± SD) or medians and 
interquartile range (median [IQR]), as appropriate. Variables with skewed distribution were 
log transformed before further analysis.  
To test differences between treatment arms taking the lean-obese status into account, we 
first used two-way ANOVA with interaction. In case of a statistically significant interaction 
term, results were reported separately for the lean and obese group otherwise two-way 
ANOVA without interaction were used to adjust the treatment effect for the lean/obese 
status and results were reported for the combined groups.  
In the case that variables were not normally distributed before or after log-transformation, 
differences between treatments were tested by one-way Kruskal–Wallis analysis of 
variance applied separately to samples of obese and lean subjects.  
Pearson's correlation coefficients were used to describe inter-individual (across subjects) 
correlations between variables and also used to calculate intra-individual (within subject) 
correlation between variables measured during the OGTT and isoglycemic test. To test 
whether the mean intra-individual correlations are different from zero, one-sample t-test 
were performed after normalizing the single intra-individual correlations by applying 
Fisher's-z-transformation.  
P-values from two-sided tests less than or equal to 5% were considered to indicate 
significant differences.  
AUCs of the various compounds are calculated with the trapezoidal rule. Changes in the 
incretin effect were calculated by AUC of insulin, C-peptide, glucagon, GLP-1 and GLP-2 
during OGTT and isoglycemic test. Calculated ΔAUC was defined as AUC during OGTT 
minus AUC during isoglycemic test. Due to the positive skewness, these AUCs were log-
transformed (natural logarithm). Differences of these ΔAUC before and after intervention 
were calculated. 
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Results 
 
Recruitment and enrollment of study subjects 
Subjects were recruited by newspaper advertisement, flyer, and during an official 
information event at the German Diabetes Center. More than 130 interested persons 
contacted us by telephone as resonance to the newspaper advertisement. During the 
telephone call potential participants got first information about study procedure and 
duration, allowance, medical examination and measurements.  
 
 
 
Fig. 11 Enrollment and allocation of participants according CONSORT flow diagram 
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After written informed consent, 39 subjects were screened for the study throughout 
October 2011 until August 2012. Of the screened persons 13 subjects did not fullfill the 
inclusion criteria (e.g. 2 subjects because of antibiotic treatment, 1 subject because of 
weight changes before study start, 1 subject because of common cold during run-in 
phase), 4 subjects abstained from the study as they did not want to follow dietary 
restrictions, 1 person refrained from participating without giving any reasons (figure 11). 
 
 
Table 4 Baseline characteristics of study cohort 
 Combined Lean Obese 
Subjects [female / male] 11 / 10 6 / 5 5 / 5 
Age [years] 50±7 49±7 51±7 
BMI [kg/m2] 29.2±7.0 23.6±1.7 35.5±4.9 
Waist circumfence [cm] 99.1±17.7 83.3±11.5 111.9±9.0 
HbA1c [%] 5.3±0.4 5.2±0.3 5.5±0.4 
Fasting BG [mg/dl] 78±7 77±9 79±6 
Fasting FFA [µmol/l] 439 [370-631] 439 [246-522] 462 [386-678] 
OGIS [ml/min/m2] 528±92 569±94 482±67 
Adaptation index 0.808 [0.511-0.924] 0.615 [0.509-0.924] 0.830 [0.720-0.957] 
Disposition index 3.09 [2.68-5.09] 2.76 [2.33-3.08] 4.77 [4.33-7.55] 
Insulinogenic index  179 [123-396] 135 [94-409] 219 [147-395] 
hsCRP [mg/dl]§ 0.09 [0.05-0.29] 0.05 [0.04-0.10] 0.30 [0.08-0.40] 
Blood pressure sys [mmHg] 138±21 133±23 143±16 
Blood pressure dias [mmHg] 85±11 77±9 93±6 
Resting energy expenditure [kcal] 1629±285 1457±248 1819±191 
Gastric emptying [t½]# 84±34 90±36 78±32 
Treatment adherence* 21/21 11/11 10/10 
Mean ± SD and median [interquartile ranges] are given for normally and log-normally distributed 
data, respectively. Significant differences (p<0.05) between lean and obese subjects are high 
lightened in bold (unpaired t-test). Resting energy expenditure and hsCRP§ were determined 
before intervention. The half time (t1/2) of gastric emptying# was measured using the 13C-octanoic 
acid breath test. Compliance* was confirmed by tablet counting. 
 
 
The remaining 21 participating subjects were 11 lean, healthy control subjects (6 females 
and 5 males) and 10 obese non-diabetic subjects (5 females and 5 males) with a mean 
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age ± SD of 49±7 years and 51±7 years, respectively (table 4). Five of the lean subjects 
received placebo and 6 received L. reuteri. Of the obese subjects, 5 received placebo and 
5 received L. reuteri.  
 
Baseline characteristics of study cohort 
As expected, the obese group had a higher BMI compared to the lean subjects (23.6±1.7 
vs. 35.5±4.9 kg/m2, p<0.001), elevated levels of body fat mass (40±9 vs.28±6 %, p<0.003) 
and lean body mass (63.5±9.5 vs. 50.7±11.1 kg, p<0.02), but did not differ in regard to 
concentrations of fasting plasma glucose, glucose tolerance as determined by oral 
glucose tolerance test (OGTT), gastric emptying, treatment adherence, HbA1c and 
systolic blood pressure (table 4). Insulin sensitivity assessed by OGIS was lower in obese 
subjects, whereas hsCRP and diastolic blood pressure were higher. Treatment adherence 
as determined by capsule counting that showed 99.8% compliance in obese and 100% in 
lean subjects. Likewise, there were no differences of treatment adherence, confirmed by 
tablet counting between L. reuteri- and placebo- groups. 
 
 
 
Fig. 12 Abundance of bacterial populations in faecal samples 
Total bacterial load (eubacteria), enterobacterial content (enterobac.), and Lactobacillus content 
(Lac. spp), were comparable between intervention- (blue) and placebo-group (red), and did not 
change upon treatment with L. reuteri. L. reuteri content was increased at the end of trial 
(p<0.0001) and enlarged compared to placebo (***p<0.0001). Abundance of bacterial populations 
was measured by quantitative real-time PCR. Shown are mean ± SD, Fischer´s exact t-test. 
 
Abundance of bacterial populations in faecal samples 
Faecal samples were obtained from all 21 subjects before intervention, and from all but 
one subject at the end of intervention. From one lean subject of the placebo group we did 
not receive a sample after intervention. Another lean subject of the placebo group was 
 
 45
tested positive for L. reuteri in L. reuteri qPCR before intervention (0.249 DNA-copies) and 
was still positive after intervention (0.041 DNA-copies), but with lower concentration. All 
other faecal samples were L. reuteri-negative before intervention.  
Stool samples of the subjects ingesting L. reuteri were tested positive upon treatment in L. 
reuteri qPCR, whereas those of the placebo treated subjects remained negative 
(p<0.0001). As shown in figure 12, Treatment with neither L. reuteri nor placebo lead to 
an alteration in total bacterial load, enterobacteria or Lac. spp. content. Interestingly, these 
findings were preserved, and comparable between lean and obese subjects, independent 
on the group they belong to. Additionally, in the intervention group there were no 
differences in L. reuteri content between lean and obese subjects. 
 
Anthropometry 
The anthropometric parameters body weight [kg], BMI [kg/m2], body fat mass [%], and 
lean body mass [kg] of the two treatment groups were unaffected by L. reuteri or Placebo 
treatment (table 5). Also waist/hip-ratio, blood pressure [mmHg] and pulse [/min] of all 
subjects remained stable during the study (data not shown). 
 
Table 5 Anthropometric data before and after intervention in the respective groups.  
  L. reuteri Placebo 
Body weight [kg] 
Before 87±23 87±22 
After 87±23 88±22 
Body fat [%] 
Before 35±7 34±11 
After 33±8 34±11 
Lean body mass [kg] 
Before 56±13 56±12 
After 58±13 56±12 
Intrahepatocellular lipids [%] 
Before 1.6 [0.5 - 15.9] 2.4 [1.8 - 14.7] 
After 2.7 [0.6 - 14.9] 1.5 [0.9 - 21.7] 
Intramyocellular lipids [%]     
m. soleus 
Before 1.4 [0.9-1.7] 1.5 [0.9 - 2.3] 
After 1.1 [0.6 - 2.2] 1.2 [0.7 - 2.1] 
Intramyocellular lipids [%]     
m. tibialis ant. 
Before 0.5 [0.3 - 1.0] 0.8 [0.4 - 0.8] 
After 0.7 [0.6 - 1.0] 0.6 [0.2 - 0.8] 
Mean ± SD and median [interquartile ranges] are given for normally and log-normally distributed 
data, respectively. To test for differences between treatment arms adjusted for body weight, we used 
two-way ANOVA. Neither before nor after intervention, significant differences in anthropometric data 
and ectopic fat content between the L. reuteri and the placebo group, were found. 
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Fig. 13 Ectopic lipid content in L. reuteri and placebo treated subjects  
L. reuteri (blue) and placebo (red) treated subjects, before and after 
intervention. Shown are box and whiskers, the line in the box gives median, 
bars and boxes give interquartile range (IQR), error bars give the minimum 
and maximum. Intrahepatocellular lipids (HCL) (A), intramyocellular lipids 
(IMCL) measured in musculus (m.) soleus (B) and m. tibilais anterior (C). 
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Ectopic lipid content  
Ectopic lipid content was assessed in 8 lean (4 L. reuteri, 4 placebo) and 7 obese (4 L. 
reuteri, 3 placebo) subjects. Two subjects did not undergo this investigation as they 
suffered from claustrophobia, one subject had implants with contraindication for MRS, and 
two did not participate in this assessment for other reasons.  
Ingestion of L. reuteri did not affect ectopic lipid content measured by MR spectroscopy - 
neither for intrahepatocellular lipid content (HCL) nor for intramyocellular lipid content 
(IMCL) determined in the musculus (m.) soleus and m. tibilais anterior (table 5, figure 13 
A-C). The BMI correlated with the intrahepatocellular lipid content before (r=0.722, 
p<0.003) and after intervention (r=0.625, p<0.014) but not with IMCL in m. soleus and m. 
tibilais anterior - neither before nor after intervention. 
 
 
Tissue-specific whole body and hepatic insulin sensitivity  
As expected, lean subjects showed better (higher) whole-body insulin sensitivity 
compared to obese subjects before (M-Value 9.6 [IQR 6.4 – 11.4] vs. 5.4 [3.7 – 7.9] 
mg/kg*min, p<0.05) and after intervention (M-Value 8.5 [7.4 - 10.3] vs. 7.0 [4.0 - 8.3] 
mg/kg*min, p<0.05, figure 14 A). The comparison of whole-body insulin sensitivity 
between L. reuteri- and placebo-group neither showed differences before (M-Value 8.2 
[5.7 - 10.0] vs. 6.4 [4.4 - 11.1]) nor after intervention (M-Value 7.4 [6.5 - 11.5] vs. 8.0 [6.6 - 
9.1]). Likewise, intervention did not alter whole body insulin sensitivity.  
L. reuteri neither affected endogenous glucose production (EGP) at baseline (1.9±0.4 vs. 
1.6±0.3 mg/kg*min, data not shown) nor insulin-stimulated EGP suppression. EGP was 
also comparable between L. reuteri- and placebo-group before and after intervention 
(figure14 B). 
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A 
     
 
B 
 
Fig. 14 Results from the hyperinsulinemic-euglycemic clamp  
before and after intervention in L. reuteri (blue), and placebo (red) treated 
groups. M-Value represents the whole body insulin sensitivity (A). Endogenous 
glucose production (EGP) represents the hepatic insulin sensitivity (B). Given are 
box and whiskers, the line in the box gives median, bars and boxes give 
interquartile range (IQR), error bars give the minimum and maximum.  
 
 
 
Energy expenditure and substrate oxidation 
The resting energy expenditure (REE) measured in kcal at baseline and during clamp 
differed between lean and obese subjects (table 4) and did not change during the study. 
In line with the results from hyperinsulinemic-euglycemic clamp, the substrate oxidation, 
especially the oxidative and non-oxidative glucose utilization, which both increased during 
clamp, showed neither differences between groups nor towards intervention (figure 15 A).  
Lipid oxidation rates during hyperinsulinemia were reduced by L. reuteri 94% and by 
placebo 102% compared to baseline, without any differences between both groups 
(figure 15 B). 
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Fig. 15 Lipid oxidation and glucose utilization before and after intervention 
Bars show the glucose utilization (A) and lipid oxidation rates (B) in L. reuteri (blue) and 
placebo (red) treated groups, respectively. Lipid oxidation and glucose utilization were 
assessed at baseline and during steady state conditions of hyperinsulinemic-euglycemic 
clamp. Hatched bars show the non-oxidative glucose utilization (non-ox), checkered bars 
show oxidative glucose utilization (ox). Mean and SD are given before and after intervention.  
 
 
 
Glucose tolerance  
Blood glucose concentrations measured from OGTT and isoglycemic i.v. glucose infusion 
test (infusion of 20% glucose solution) remained unchanged upon treatment (figure 16). 
Likewise, the total glucose infusion rate calculated in total g glucose showed no 
differences upon treatment (before 26.2 [14.5 - 43.6] vs. after 29.7 [16.0 – 35.0]). Glucose 
infusion rates of lean and obese subjects differed after (13.0 [6.9 - 29.6] vs. 22.0 [37.5 – 
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47.9], p<0.004), but not before intervention (23.2 [10.3 – 26.2] vs. 22.3 [19.3 – 51.3], 
p=0.3073). 
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Fig. 16 Blood glucose concentrations during OGTT and isoglycemic i.v. glucose infusion 
OGTT (A) and isoglycemic i.v. glucose infusion (B) before and after Intervention of L. reuteri- (blue) 
and placebo-group (red), respectively. Shown are data from lean (triangles) and obese subjects 
(circles) before (open symbols) and after intervention (closed symbols) as mean and SEM. *p<0.05 vs. 
baseline. 
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Insulin secretion and incretin effect 
Intravenous and oral glucose-stimulated C-peptide and insulin levels were determined to 
assess β-cell function. Insulin and C-peptide secretion were stimulated to a higher extend 
by orally than by intravenously applied glucose in all groups (p<0.01) as expected. 
After Intervention, insulin secretion was increased 20 min and 60 min after glucose 
application, in parallel with increased C-peptide levels at these time points, while glucagon 
remained unaltered. The increased concentrations of insulin and C-peptide were 
detectable in lean and obese subjects (figure 17 A-B). Fasting concentrations of 
glucagon differed between lean and obese subjects before (p<0.05) but not after 
intervention (p=0.08). By trend glucagon concentrations were higher in obese compared 
to lean subjects (figure 17 C). 
 
Comparison of the relative difference of ΔAUC before intervention versus ΔAUC after 
intervention, to assess the incretin effect, showed that ΔAUC of insulin and C-peptide 
were increased in the L. reuteri-group at the end of the study (p<0.05), but not in the 
placebo group (figure 18 A-B). When we determined single time points of insulin and C-
peptide during oral glucose stimulation, the higher insulin and C-peptide concentrations in 
the L. reuteri group at the end of the trial was seen with significantly increased 
concentrations at 20 and 60 min of glucose stimulation (p<0.05, figure 17 A-B). The 
maximal response (peak at 60 min) for insulin and C-peptide was increased at the end of 
the study in the intervention group (p<0.016, p<0.018, respectively). Concentrations of 
glucagon remained stable throughout the study and were unaffected by intervention 
(figure 18 C). There were no glucose-stimulated alterations and no maximal responses 
(peak) detectable for glucagon. Glucose-stimulated concentrations of glucagon showed 
no differences between lean and obese subjects (figure 17 C).  
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Fig. 17 Concentrations of insulin, C-peptide and glucagon during OGTT  
Comparison of insulin (A), C-peptide (B) and glucagon (C) during OGTT before versus after 
intervention of L. reuteri- (blue) and placebo-group (red), respectively. Shown are data from lean 
(triangles) and obese (circles) subjects before (open symbols) and after intervention (closed 
symbols). Mean and SEM, *p<0.05 before vs. after intervention. 
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Fig. 18 ΔAUC of Insulin, C-peptide and glucagon 
Comparison of Δ area under the curve (AUC) of insulin (A), C-peptide (B) and glucagon (C) before 
versus after intervention of L. reuteri- (blue) and placebo-group (red), respectively. Shown are 
ΔAUC, calculated as delta of AUC of OGTT and AUC of the isoglycemic test, before (open 
symbols) and after intervention (closed symbols). Mean and SEM, *p<0.05 ΔAUC before vs. ΔAUC 
after intervention. 
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Indices of β-cell function calculated by validated mathematical model analyses taking 
glucose, insulin and C-peptide values of OGTT into account, the adaptation index, the 
disposition index, and the insulinogenic index, were increased in the L. reuteri-group (p< 
0.05) after treatment and altered when compared to the corresponding indices of the 
placebo-group, which remained unchanged (table 6). 
 
 
Table 6 Changes of indices of β-cell function upon intervention 
  L. reuteri Placebo 
OGIS 
before 476±95 533±100 
after 521±128 527±74 
Adaptation index 
before 0.578 [0.480- 0.835] 0.765 [0.489 - 0.947] 
after 0.793 [0.606 - 0.874]* 0.728 [0.505 - 0.822] 
Disposition index 
before 3.05 [2.21 - 4.28] 3.89 [2.24 - 5.78] 
after 3.74 [2.85 - 7.97]* 2.69 [2.24 - 4.59] 
Insulinogenic index 
before 153 [143 – 660] 551 [252 – 714] 
after 264 [131 – 307] 261 [156 – 472]* 
Mean ± SD and median [interquartile range] are given for normal and log-normal distributed data, 
respectively. Significant differences (before/after intervention) of L. reuteri vs. placebo are 
highlighted in bold, *significant difference before/after intervention within the treatment group, 
p<0.05. OGIS is an index for insulin sensitivity, while the adaptation index, the disposition index, 
and the insulinogenic index are indices of β-cell function taking insulin sensitivity into account.  
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Incretin secretion 
The fasting plasma concentrations of GLP-1, GLP-2 and GIP were in a range as 
expected. The concentrations after intervention were median 7.0 (5.0-8.0) pmol/l for GLP-
1, 8.0 (8.0-10.0) pmol/l for GLP-2 and mean 62.3±35.5 pg/ml for GIP and did not change 
when compared to baseline levels except for GLP-1 (figure 19 A-C). During the OGTT we 
observed an increase in plasma concentrations for all three gut hormones with a 
maximum seen at 30 min for GLP-1, 60 min for GLP-2 and GIP (figure 19 A-C), before 
and after intervention. The maximal response (peak) for GLP-1 and GLP-2 was increased 
at the end of the study in the intervention group for lean subjects (p<0.02 and p<0.04, 
respectively) but not for obese subjects. The maximal response (peak) for GLP-1 differed 
in the L. reuteri group after intervention compared to placebo (p<0.04, figure 19). 
 
After treatment fasting plasma GLP-1 levels were increased within the intervention group 
(p<0.02, min 0), and were by trend increased (p=0.052, min 0) when compared to the 
placebo group. Glucose stimulated GLP-1 levels were higher after treatment at minute 20 
(p<0.03), 30 (p<0.01), 60 (p<0.01), 120 (p<0.05), and 180 (p<0.03) of the OGTT within the 
L. reuteri group (figure 19 A), and increased compared to placebo at minute 20 (p<0.01), 
30 (p<0.01), 60 (p<0.01), 120 (p<0.05), and 180 (p<0.03) of the OGTT. Likewise, plasma 
GLP-2 levels were by trend increased after treatment at minute 20 (p<0.057) and 60 
(p<0.065), within the L. reuteri group (figure 19 B), and increased compared to placebo at 
minute 20 (p<0.05) and 60 (p<0.02). Glucose stimulated GLP-1 and GLP-2 levels, 
measured at several time points during OGTT were increased after intervention. 
 
As GLP-1 and GLP-2 are co-secreted, we investigated their correlation. Plasma GLP-1 
and GLP-2 concentrations from OGTT samples showed a similar pattern and correlated 
positively intra-individually before (r=0.86; p<0.0001) and after intervention (r=0.82; 
p<0.0001). Likewise, AUCs of GLP-1 and GLP-2 correlated with each other before (r= 
0.87, p<0.0001) and after (r= 0.95, p<0.0001) intervention. Further, GLP-1 and GLP-2 
correlated intra-individually with insulin (r=0.74 p<0.0001 and r=0.76 p<0.0001 
respectively) and C-peptide concentrations (r=0.79 p<0.0001 and r=0.72 p<0.0001 after 
intervention respectively) during OGTT but not during isoglycemic i.v. glucose infusion test 
(data not shown). 
Glucose stimulated AUC of GLP-1 (during OGTT) was increased in the L. reuteri group 
after intervention (p<0.003) and elevated when compared to the placebo group (figure 19 
A). Similarly, glucose stimulated AUC of GLP-2 was increased in the intervention group 
compared to placebo (p<0.029, figure 19 B). GIP remained unchanged in the intervention 
group and compared to placebo (figure 19 C).  
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Fig. 19 Gut peptides secretion during OGTT  
Gut peptides concentrations during OGTT before versus after intervention in the L. reuteri- (blue) and 
placebo-group (red), respectively. Shown are data from lean (triangles) and obese (circles) subjects 
before (open symbols) and after intervention (closed symbols) as mean and SEM. Glucagon-like 
peptide (GLP)-1 (A) and GLP-2 (B), glucose-dependent insulinotropic peptide (GIP) (C), *p<0.05 before 
vs. after intervention. 
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Fig. 20 ΔAUC of glucagon like peptides and glucose-dependent insulinotropic peptide 
Comparison Δ area under the curve (AUC) of glucagon like pepdide (GLP)-1 (A), GLP-2 (B) 
and glucose-dependent insulinotropic peptide (GIP) (C) before versus after intervention of L. 
reuteri- (blue) and placebo-group (red), respectively. Shown are ΔAUC, calculated as delta of 
AUC of OGTT and AUC of isoglycemic test, before (open symbols) and after intervention 
(closed symbols). Mean and SEM, *p<0.05 ΔAUC before vs. ΔAUC after intervention. 
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The ΔAUC of GLP-1 calculated as ‘ΔAUC after - ΔAUC before’ to assess the incretin 
effect, was increased at the end of the study compared to placebo (p<0.004) and tends to 
be increased after intervention within the L. reuteri-group (p=0.087) (figure 20 A). The 
ΔAUC of GLP-2 was increased after intervention in the L. reuteri-group (p< 0.02, figure 
20 B) and significantly increased when compared to the placebo-group (p<0.004). ΔAUC 
of GIP remained unchanged in both groups (figure 20 C). REE before (-0.74, p<0.01; -
0.63, p<0.01) and after intervention (-0.64, p<0.01; -0.67, p<0.001) as well as body weight 
before (-0.63, p<0.05; -0.52, p<0.01) and after (-0.75, p<0.001; -0.75, p<0.001) 
intervention showed an inverse inter-individual correlation with the AUCs of GLP-1 and 
GLP-2. 
 
Systemic Inflammation 
Obese non-diabetic subjects had higher concentrations in the fasting hsCRP (figure 21; 
p<0.004 and p<0.002) and glucose-stimulated state, during OGTT (p<0.003 and 
p<0.002), similar to pro- and anti-inflammatory cytokines (IL-1ra, MCP-1, TNF-alpha, 
table 7) before and after intervention. These cytokine concentrations were in an expected 
range. There were no differences between lean and obese subjects for pro-inflammatory 
IL-8 and MIP-1β levels, and for reactive oxygen species (TBARS) before, or after 
intervention (data not shown). Surprisingly, more than 80% of the IFN-γ, IL-6, IL-1β, and 
IL-10 measurements yielded values below the detection limit or were extrapolated from 
the standard curve and were therefore not analysed in this study. Upon ingestion of L. 
reuteri, all analysed pro- and anti-inflammatory immune mediators measured remained 
stable. So did the ratios between analysed pro- and anti-inflammatory immune mediators, 
including the TNF-α/IL-1ra ratio (table 7).  
 
Circulating endotoxin levels 
Fasting circulating endotoxin concentrations, as an additional parameter to assess the 
inflammatory status, also remained stable upon intervention in placebo and L. reuteri 
treated subjects. Interestingly, fasting endotoxin levels were higher in obese subjects 
before intervention compared to lean subjects (p<0.019) but did not differ between lean 
and obese subjects after intervention (p=0.169, figure 22). Similarly, the measured fasting 
endotoxin levels correlated with BMI before (r=0.443, p<0.045) but not after intervention 
(r=0.354, p=0.115). In contrast, fasting hsCRP levels correlated with the BMI before and 
after intervention (r=0.790, p<0.0001 and r=0.775, p<0.0001, respectively).  
 
Glucose-stimulated endotoxin levels at minute 120 during OGTT showed no significant 
changes upon intervention, neither in lean nor in obese subjects. But similar to the fasting 
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levels, glucose-stimulated endotoxin levels differed between lean and obese subjects 
before (p<0.049) but not after intervention (data not shown) and correlated with BMI 
before (r=0.503, p<0.020) but not after intervention (r=0.379, p=0.089). 
 
obese lean
0.00
0.25
0.50
0.75
before a fte r
L.
 re
ut
er
i
L.
 re
ut
er
i
Pl
ac
eb
o
Pl
ac
eb
o
be fo re a fte r
L.
 re
ut
er
i
L.
 re
ut
er
i
Pl
ac
eb
o
Pl
ac
eb
o
hs
C
R
P 
(m
g/
dl
)
 
Fig. 21 Fasting hsCRP concentrations 
Comparison of fasting hsCRP concentrations of the L. reuteri (blue) and 
the placebo-group (red), before (open) and after intervention (closed bars) 
in lean and obese subjects. Shown are mean and SEM. 
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Fig. 22 Fasting endotoxin concentrations  
Comparison of fasting endotoxin (lipopolysaccharide, LPS) concentrations 
of the L. reuteri- (blue) and the placebo-group (red), before (open) and 
after intervention (closed bars) in lean and obese subjects. Shown are 
mean and SEM. 
 60
Circulating adipokine concentrations 
Ingestion of L. reuteri did not affect serum concentrations of leptin or adiponectin, as 
markers secreted by the adipose tissue. Fasting leptin was significantly higher in obese 
compared to lean subjects before (p<0.05) and after intervention (p<0.05). Subgroup 
analyses showed no differences based on the intervention neither in obese nor in lean 
subjects (figure 23). The glucose-stimulated leptin concentrations showed similar results 
(data not shown). 
 
Leptin concentrations correlated positively with LPS (r=0.512, p<0.036) in lean and obese 
subjects, and this association persisted after adjustment for BMI (r=0.512, p<0.036). 
Further, intra-individual leptin correlated inversely with intestinotrophic GLP-2 (r=-0.267; 
p<0.028) and positively with the pro-inflammatory cytokines MIP-1β (r=0.464, p<0.001) 
and TNF-α (r=0.287, p<0.033). Whereas leptin correlated inversely with peripheral insulin 
sensitivity (r=-0.433, p<0.05), significance disappeared after adjustment for BMI (r=0.462, 
p=0.221). 
 
Fasting adiponectin levels remained stable upon intervention and did not differ in 
subgroups (figure 24), as well as glucose-stimulated adiponectin levels, which showed no 
differences, neither in lean nor in obese subjects (data not shown).  
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Fig. 23 Fasting leptin concentrations 
Comparison of fasting leptin concentrations of the L. reuteri- (blue) and 
the placebo-group (red), before (open) and after intervention (closed 
bars) differentiated between lean and obese. Shown are mean and SEM. 
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Fig. 24 Fasting adiponectin concentrations 
Comparison of fasting adiponectin concentrations of the L. reuteri- (blue) 
and the placebo-group (red), before (open) and after intervention (closed 
bars) differentiated between lean and obese. Shown are mean and SEM. 
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Table 7 Systemic inflammatory mediators 
  
L. reuteri 
 
Placebo 
 
Lean Obese Lean Obese 
hsCRP (mg/dl) 
before 0.065 [0.030 - 0.195] 0.290 [0.120 – 0.375] 0.050 [0.040 – 0.115] 0.310 [0.075 – 1.045] 
after 0.065 [0.030 – 0.200] 0.280 [0.150 – 0.345] 0.070 [0.055 – 0.085] 0.210 [0.095 – 0.745] 
IL-1ra (pg/ml) 
before 643.8 [572.1 – 813.9] 1714.0 [1217.0- 2003.7] 736.7 [570.8 - 874.4] 1270.6 [801.8 – 2543.1] 
after 544.8 [510.3 – 1010.7] 1728.7 [1451.4 – 2615.9] 651.8 [617.7 - 693.9] 1402.7 [929.4 – 2764.4] 
MCP-1 (pg/ml) 
before 242.5 [211.3 – 280.6] 339.5 [252.2 – 506.1] 326.6 [212.5 - 385.9] 544.8 [507.5 – 565.4] 
after 255.7 [201.0 – 438.1] 297.0 [210.6 – 558.7] 253.0 [222.6 - 280.9] 553.1 [391.0 – 651.1] 
TNF-α (pg/ml) before 3.47 [2.77 – 5.70] 10.90 [2.98 – 65.55] 4.16 [2.53 - 6.80] 30.56 [6.48 – 54.68] 
after 4.48 [2.97 – 20.29] 6.32 [4.05 – 58.80] 2.68 [2.09 - 4.17] 29.50 [6.48 – 45.13] 
MIP-1β (pg/ml) before 71.51 [51.29 – 121.11] 232.02 [96.92 – 300.83] 70.88 [66.69 – 74.49] 154.19 [112.82 – 457.22] 
after 63.15 [42.15 – 136.14] 172.64 [87.41 – 208.48] 68.79 [63.78 – 99.37] 135.60 [113.53 – 473.01] 
TNF-α/IL-1ra 
ratio 
before 0.006 [0.004 – 0.013] 0.006 [0.003 – 0.036] 0.008 [0.003 -0.015] 0.010 [0.008 – 0.023] 
after 0.009 [0.005 – 0.024] 0.004 [0.003 – 0.032] 0.004 [0.003 – 0.016] 0.009 [0.008 – 0.019] 
Serum concentrations of inflammatory markers are given as median [interquartile range], for the log-normal distributed data. To test for differences 
between treatment arms adjusted for body weight, we used two-way ANOVA. No significant changes in systemic inflammatory mediators between L. 
reuteri and placebo group neither before nor after intervention were found.     
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Concentrations of free fatty acids and triglycerides  
Free fatty acid (FFA) and triglyceride (TG) concentrations differed between lean and 
obese subjects (p<0.05) and remained unchanged upon intervention. As expected FFA 
concentrations were significantly supressed during OGTT (p<0.01, figure 25 A), while TG 
remained stable (figure 25 B).  
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Fig. 25 Free fatty acids (FFA) and triglycerides (TG) during OGTT  
Comparison of free fatty acids (FFA) (A) and triglycerides (TG) (B) during OGTT, before versus 
after intervention of L. reuteri- (blue) and placebo-group (red), respectively. Shown are data from 
lean (triangles) and obese (circles) subjects before (open symbols) and after intervention (closed 
symbols). Shown are median and SEM, * p<0.05 before vs. after intervention. 
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Discussion 
 
This is the first study demonstrating that ingestion of L. reuteri over 4 weeks modulate the 
secretion of insulin, C-peptide, and the gut hormones GLP-1 and GLP-2, in glucose tolerant 
lean and obese humans. In contrast, peripheral and hepatic insulin sensitivity and associated 
parameters like body mass, ectopic fat content, and the levels of systemic inflammatory 
mediators, adipokines, endotoxin and oxidative stress remained unchanged (figure 26).  
 
 
 
Fig. 26 Schematic overview of the probiotic effects 
Specific questions which have been addressed are marked red,  means improved effects. For 
further details see main text. 
 
 
Good treatment adherence throughout the study and safety of the probiotic strain L. reuteri 
Subjects who ingested the probiotic strain L. reuteri or placebo showed good compliance, 
which was confirmed by treatment adherence measured by capsule counting and detection 
of L. reuteri in fecal samples. Samples from persons ingesting L. reuteri were tested positive 
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for the presence of the bacteria, whereas placebo treated persons remained negative for L. 
reuteri in more than 90%, indicating very good treatment adherence and dietary restriction of 
other probiotic supplementation. Further, ingestion of L. reuteri and placebo was well 
tolerated, was safe in handling and dosage, and no side-effects were reported in either 
treatment arm. 
 
Ingestion of the probiotic strain L. reuteri modulates plasma gut peptides 
The incretin GLP-1 stimulate glucose-dependent the insulin secretion (Drucker, 2001b; 
Drucker, 2001a; Drucker, 2006). GLP-2 primarily targets the intestinal mucosa promoting 
growth and intestinal integrity (Drucker et al., 1996; Martin et al., 2005; Cani et al., 2009b). 
Both GLP-1 and GLP-2 are processed from proglucagon with equal efficiency and secreted 
by the intestinal L-cells simultaneously and in equimolar amounts (Drucker, 2002; Drucker, 
2001b; Orskov et al., 1986; Holst JJ et al., 1997). Indeed, GLP-1 and GLP-2 concentrations 
measured in our study were correlated positively. Both gut hormones correlated intra-
individually also with insulin and C-peptide concentrations during OGTT, but not during the 
isoglycemic test, as expected and suggestive for an efficient measurement of the incretin 
effect. The association of GLP-2 concentrations with those of insulin probably is indirect and 
can be explained by the co-secretion of GLP-2 and the incretin GLP-1. After treatment with L. 
reuteri, the mean increase of GLP-2 ΔAUC during OGTT was 43% compared to baseline, 
and this was parallel to the 76% increase seen for GLP-1. Probably only due to the limited 
number of participants, the ΔAUC GLP-1 increase was only significant compared to placebo 
but not within the intervention group. Therefore an involvement of both peptides, the 
intestinotrophic GLP-2 and the insulinotropic GLP-1, can be supposed. Our results 
complement the findings from an animal study, investigating the effects of a prebiotic 
treatment on the GLP-1 and GLP-2 concentrations (Cani et al., 2009b; Cani et al., 2005), and 
show that the probiotic strain L. reuteri increases the glucose-stimulated release of the 
incretin GLP-1 and the intestinotrophic GLP-2 in glucose tolerant human subjects. 
In further animal models, testing prebiotics increased serum GLP-1 concentrations, lower 
fasting glucose, improved insulin sensitivity as indicated by HOMA-IR were reported. In this 
study pregnant Goto–Kakizaki rats were fed with dietary-resistant starch, suggesting that 
dietary-resistant starch with its known effects on the gut microbiota, improved maternal 
glycemic control (Shen et al., 2011). Similar results were obtained in a study with Wistar rats 
fed with prebiotic fiber. The treatment resulted in higher AUC GLP-1 levels during OGTT 
accompanied by significantly lower AUC glucose at the end of the study (Reimer et al., 
2012). The only clinical trial, focusing on the effects of prebiotic treatment on incretins 
showed an association of prebiotic supplementation with increased GLP-1 and peptide YY 
concentration as well as with decreased postprandial plasma glucose responses after a 
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standardized meal in healthy human subjects (Cani et al., 2009a). However, no data exist 
regarding the effects of probiotic supplementation on incretin secretion. In our clinical trial we 
showed that administration of probiotic strain L. reuteri increased incretin, insulin and C-
peptide responses in glucose-tolerant human subjects.  
 
Administration of L. reuteri increases glucose-stimulated release of insulin and C-peptide 
The insulinotropic gut-derived hormone GLP-1 shows decreased concentration and impaired 
function in type 2 diabetic subjects (Drucker, 2006; Wong and Brubaker, 2006; Vilsboll et al., 
2001; Nauck et al., 1986). In our clinical trial with glucose-tolerant subjects, glucose 
stimulated GLP-1 concentrations were increased after administration of L. reuteri. 
Interestingly, the increase of GLP-1 levels occurred mainly in lean persons. However, the 
function of GLP-1, if defined as incretin effect (ΔAUC of GLP-1, insulin and C-peptide) was 
enhanced in the entire intervention group, suggesting that both lean and obese subjects may 
benefit from the intervention with L. reuteri.  
Additionally, the effect of L. reuteri ingestion on the intestinal incretin response was 
accompanied by higher insulin and C-peptide responses during the OGTT, but not when the 
OGTT was mimicked by the isoglycemic intravenous glucose infusion. The mean increase of 
the ΔAUC insulin and C-peptide concentrations were elevated by 49% (46% for lean, 51% 
for obese individuals) and 55% (39% for lean, 74% for obese individuals), respectively, by 
the intervention. Thus, the incretin effect, as defined by changes of ΔAUC insulin and C-
peptide, was improved by the intervention in our study cohort.  
The gut hormones GLP-1 and GIP are proportionately released upon glucose or meal intake 
(Drucker, 2006; Holst JJ et al., 1997; Ferrannini et al., 1982) and they stimulate insulin 
secretion mediated by increasing blood glucose levels (Drucker, 2006; (Vilsboll et al., 
2003a). However, the molecular mechanisms by which incretins stimulate insulin secretion 
have not been fully elucidated. Under physiological conditions, incretin-mediated stimulation 
of insulin secretion results from a generally enhanced beta-cell function (Muscelli et al., 
2006). In patients with T2D, glucose- or meal-stimulated GLP-1 secretion is reduced 
compared to lean and obese non diabetic subjects (Vaag et al., 1996; Vilsboll et al., 2003b). 
In contrast, GLP-1 infusion stimulates insulin secretion in patients with T2D indistinguishable 
to control subjects (Kjems et al., 2003; Quddusi et al., 2003). This observation demonstrate, 
that the lack of GLP-1 secretion can counteracted by GLP-1 infusion, suggesting that the 
incretin mediated β-cell responsiveness to glucose is only partially affected, in patients with 
T2D.  
In our clinical trial we showed that administration of L. reuteri leads to increased glucose-
stimulated GLP-1 release, as well as increased insulin and C-peptide responses in lean and 
obese glucose-tolerant human subjects. Similarly, we observed alterations of indices of β-cell 
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function, indicating an improved β-cell function in L. reuteri treated persons, suggesting that 
increased insulin release is incretin mediated. 
 
Ingestion of L. reuteri might accelerate intestinal motility 
The majority of the intestinal K-cells secreting GIP are located in the proximal duodenum 
whereas the glucagon-like peptide secreting L-cells are located in the small and large 
intestine and GLP-1 is mainly synthesized and released from enteroendocrine L-cells in the 
distal ileum and colon (Martinez-Rodriguez and Gil, 2012; Dupre et al., 1973; Drucker, 2006; 
Drucker and Nauck, 2006). Since the concentrations of GIP remained unaffected, while the 
GLP-1 and GLP-2 secretion was increased, it may be concluded that the ingestion of L. 
reuteri might accelerate intestinal motility and improve mucosal functions. However, all 
recruited healthy subjects reported normal intestinal motility and stool frequency. This finding 
is in line with the results of a study investigating the effect of the consumption of a symbiotic 
product containing lactitol and L. acidophilus NCFM, twice daily over 2 weeks in a double-
blind parallel trial with forty-seven healthy elderly subjects. This intervention only slightly 
increased stool frequency, improved intestinal motility and altered several markers 
suggestive for an improved mucosal integrity (Ouwehand et al., 2009). 
 
Administration of L. reuteri had no impact on glucagon concentrations 
The basic functions of glucagon is to counter-regulate the actions of insulin, and to 
maintaining physiological levels of blood glucose by inducing hepatic glucose production (Ali 
and Drucker, 2009). Glucagon may further reduce body weight by modifying food intake, 
glucose and lipid metabolism as well as energy expenditure. The impact of glucagon on all 
these physiological processes is mainly due to opposing the regulation of insulin (Lefebvre 
and Luyckx, 1969; Perea et al., 1995; Jensen et al., 1991; Tan et al., 2013).  
In the development of type 2 diabetes fasting hyperglucagonemia is an early observation. 
The analysis of islet hormones in obese adolescent subjects revealed increased 
concentrations of fasting glucagon, particularly in subjects with insulin resistance or impaired 
glucose tolerance, while glucose or insulin appropriately suppressed glucagon secretion in 
these individuals (Weiss et al., 2011). In our study, investigating healthy, glucose tolerant 
subjects, the fasting concentrations of glucagon were higher in obese subjects compared to 
leans. However, there were no differences between lean and obese subjects under glucose 
stimulated conditions, and this was unaffected by the intervention with L. reuteri.  
Furthermore, the incretin hormones GIP and GLP-1 seem to have divergent effects on 
glucagon secretion, while GIP seems to stimulate, GLP-1 seems to inhibit glucagon secretion 
(De Marinis et al., 2010; Pipeleers et al., 1985). We found a glucose-stimulated increase of 
GLP-1, while GIP and glucagon concentrations remained stable.  
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Effects of probiotic L. reuteri treatment on blood glucose concentrations 
Ejtahed et al. reported from a human study that the consumption of a probiotic yoghurt 
containing L. acidophilus La5 and Bifidobacterium lactis Bb12 improved the levels of fasting 
blood glucose and HbA1c despite stable insulin concentrations and enzymatic antioxidant 
status in patients with type 2 diabetes, when compared to the control group which consumed 
conventional yoghurt (Ejtahed et al., 2012). Similarly, studies in pregnant women showed 
decreased blood glucose and less cases of gestational diabetes upon treatment with 
probiotics (Laitinen et al., 2009; Luoto et al., 2010). Laitinen et al. concluded that even in a 
normoglycemic population a dietary intervention with probiotics may improve blood glucose 
control (Laitinen et al., 2009). Our study in healthy lean and obese subjects with normal 
glucose tolerance did not show alterations of blood glucose or HbA1c, which may be due to 
the fact that we studied healthy subjects. However, our probiotic intervention improved the 
incretin and insulin serection even in this normoglycemic study population.  
 
FFA levels seem unaffected by L. reuteri administration 
Insulin sensitivity, insulin concentrations and glucose tolerance, are interrelated and each of 
these parameters may be modulated by changes in FFA concentrations (Newsholme et al., 
2007; Reaven, 1988; Savage et al., 2007). Obese subjects, often exhibit elevated plasma 
FFA levels which may inhibit insulin-stimulated glucose uptake in the periphery. In non-
diabetic humans FFA may stimulate insulin secretion and compensate for the FFA-mediated 
peripheral and hepatic insulin resistance (Boden, 2003; Boden, 1997). It has been postulated 
that G-protein-coupled receptors (GPRs) like GPR40, GPR120, whose endogenous ligands 
have been identified as long-chain free fatty acids (LCFA) (Hara et al., 2009; Hirasawa et al., 
2005; Ichimura et al., 2012), mediate at least in part the observed increase in insulin 
secretion compensating for insulin resistance (Nagasumi et al., 2009; Kebede et al., 2008; 
Lan et al., 2008; Vettor et al., 2008). Consequently, if increased insulin secretion cannot be 
maintained, FFA effects cannot be counteracted and may lead to increased hepatic glucose 
production and reduced skeletal muscle glucose uptake as early signs of insulin resistance 
(Reaven, 1988).  
In the present study, FFA concentrations were reduced by the glucose administration during 
OGTT, likely due to the increased insulin levels. There were no alterations of fasting and 
glucose-stimulated FFA concentrations due to intervention. Thus, L. reuteri modulates insulin 
secretion and gut peptide concentrations most likely without measurable FFA-mediated 
effects on whole body and hepatic insulin resistance. 
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It has been recognised that the GPRs contribute to the sensing of numerous metabolites 
such as fatty acids. Accordingly, it has been demonstrated that GPR40 and GRP120, who 
are mainly responsive to LCFA, are highly expressed by the K- and L-cells, and thereby 
could stimulate the GLP-1 and GIP secretion (Tanaka et al., 2008; Hirasawa et al., 2005). 
Thus, the digestion of TG to FFA is potentially involved in the induction of GLP-1 and GIP 
secretion (Parker et al., 2010). A study in mice by Edfalk et al. showed that GPR40 
modulates FFA-stimulated insulin secretion from β-cells not only directly but also indirectly 
via regulation of incretin secretion (Edfalk et al., 2008).  
In addition, related receptors like GPR41 and GPR43, responsive to short-chain fatty acids 
(SCFA), have been demonstrated to be expressed on L-cells as well (Tazoe et al., 2008) 
(Karaki et al., 2006) and may stimulate SCFA-triggered GLP-1 secretion at least in vitro 
(Tolhurst et al., 2012). This is of interest, since SCFA are products of bacterial fermentation 
of dietary fibre in the gut. Thus, it has been shown that SCFAs tend to increase the release 
of GLP-1 and PYY from the isolated perfused colon of rodents (Plaisancie et al., 1995; Longo 
et al., 1991).  
In our clinical trial it has been demonstrated that ingestion of the probiotic strain L. reuteri 
increased GLP-1, insulin and C-peptide secretion, without affecting FFA concentrations in 
glucose-tolerant human subjects, this suggests that other metabolic mechanisms might be 
involved. However, in our project we did not measure GPRs expression and did not 
distinguish between LCFA and SCFA, as it was not the primary aim, but in further studies 
this possible mechanism needs to be investigated. When administration of probiotic strains is 
able to increase endogenous GLP-1 release from L-cells triggered by FFA, and this 
subsequently resulted in incretin-mediated insulin release, this may become an attractive 
alternative therapeutic strategy. Since the gut hormones not only affect gut physiology, but 
also glucose homeostasis, appetite and lipid metabolism. However, further studies are 
required to evaluate the therapeutic potential of this approach.  
 
L. reuteri administration does not alter systemic and hepatic insulin sensitivity 
Intrahepatocellular lipid accumulation correlates negatively with whole body and hepatic 
insulin sensitivity as demonstrated by impaired suppression of endogenous glucose 
production and decreased hepatic glycogen synthesis during hyperinsulinemic clamps 
(Krssak et al., 2004a; Bays et al., 2004). However, in our study there was no impact of L. 
reuteri administration on hepatic and peripheral insulin sensitivity as well as hepatocellular 
and myocellular lipid content. The only other study investigating effects of the consumption of 
L. acidophilus NCFM for four weeks on insulin sensitivity in a heterogeneous study 
population of 54 males with type 2 diabetes, or impaired or normal glucose tolerance, 
revealed preserved insulin sensitivity, when compared to the placebo group (Andreasen et 
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al., 2010a). in this study, there was considerable variability among study participants and it 
was not reported whether those with an increase of insulin sensitivity were diabetic or 
normoglycemic. Only in the latter case there would be a difference to our observations with 
glucose-tolerant subjects. Since, in our study glucose-tolerant subjects remained stable in 
systemic and hepatic insulin sensitivity.  
Interestingly, Vrieze et al. recently investigated the effects of allogeneic fecal transplantation 
of lean donors on insulin sensitivity in 9 obese subjects with metabolic syndrome. They 
reported that allogeneic fecal transfer from lean donors to obese subjects improved 
peripheral insulin sensitivity, but had no effect on hepatic insulin sensitivity, body weight, and 
resting energy expenditure (Vrieze et al., 2012). Whereas this study reported an 
improvement of whole body insulin sensitivity, our results showed that whole body and 
hepatic insulin sensitivity as measured by hyperinsulinemic-euglycemic clamp with isotopic 
dilution remained unaltered upon intervention.  
 
Impact of L. reuteri on fatty liver disease 
As previous studies reported controversial results of probiotic treatment on fatty liver 
diseases. At least one study in humans suggested beneficial effects of probiotics on liver 
disease such as non-alcoholic fatty liver disease (NAFLD) and alcoholic liver cirrhosis 
(Loguercio et al., 2005), while in an open labelled pilot trial on 4 adult human subjects with 
NAFLD, all 4 subjects showed a significant increase in liver fat at the end of the intervention, 
with 3 of the 4 subjects exhibiting an increase of liver fat of more than 3% (Solga et al., 
2008). Therefore, we carefully investigated the liver for potential side effects associated with 
ingestion of L. reuteri. In our study, the hepatocellular and myocellular lipid content of all 
participants remained unchanged, possibly due to the fact that we studied healthy subjects or 
maybe explained by a different treatment regimen as compared to the other studies. 
In a study with rats, Wagnerberger et al. showed protective effects against the onset of 
fructose-induced NAFLD by Lactobacillus casei Shirota administration. In this study the 
protective effects of the probiotic strain seem to be mediated via a mechanism involving Toll-
like receptor (TLR)-4 signalling in the liver (Wagnerberger et al., 2012). Since it is known that 
the stimulation of TLR-4 by the microbial component LPS induces a proinflammatory 
response (Lu et al., 2008; Kawai and Akira, 2006; Takeda and Akira, 2004), the results of 
Wagnerberger et al. suggest that the beneficial effects of the Lactobacillus strain are 
mediated either by a protection against the increased translocation of bacterial endotoxin or 
by attenuating the effects of endotoxin at the level of the liver (Wagnerberger et al., 2012). As 
in our study with healthy subjects the hepatocellular lipid content and the LPS concentrations 
were stable, we may conclude that the beneficial effects on the liver by Lactobacillus strains 
have their impact at the early stages of associated disease of NAFLD. 
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Intervention resulted in preserved concentrations of systemic inflammatory markers, 
oxidative stress and endotoxin 
A cytokine panel of pro-inflammatory (IL-6, IL-8, IL-1β, IFN-γ, TNF-α, MCP-1, MIP-1β and 
regulatory (IL-10, IL1ra) cytokines and chemokines was assessed to investigate changes on 
the systemic inflammatory status following the intervention. As expected, lean subjects 
showed lower concentrations of hsCRP, IL-1ra, MCP-1, TNF-alpha compared to obese 
subjects, but surprisingly the detected cytokines and the TNF-α/IL-1ra ratio remained 
unaffected by the intervention. Four of the measured cytokines (IFN-γ, IL-6, IL-1β, and IL-10) 
were below the detection limit before and after the intervention, suggesting very low 
concentration of these in the systemic circulation, unaffected by intervention. This was 
against our expectations, since the cytokines IFN-γ, IL-6, IL-1β, and IL-10, are usually well 
detectable, even though in low concentrations in healthy subjects. While several other 
studies reported beneficial effects of probiotics on the inflammatory status (Rodes et al., 
2013; Sun et al., 2013; Asemi et al., 2011; Boirivant and Strober, 2007; Calcinaro et al., 
2005; Hakansson and Molin, 2011) as well as with regard to the ability to affect the systemic 
and mucosal immune system, intervention with probiotics seemed to be an accepted tool to 
modulate immune reactivity (McCarthy et al., 2003; Menard et al., 2004; Klaenhammer et al., 
2012; Bischoff and Köchling, 2012; Jirillo et al., 2012; Lomax and Calder, 2009). The lack of 
alterations of systemic inflammation observed in our study may be due to the fact that we 
investigated healthy lean and obese subjects. L. reuteri intervention in subjects with type 2 
diabetes might lead to different results, since patients with type 2 diabetes are associated 
with higher levels of systemic IL-1ra, IL-6 and TNF-α cytokines (Pham et al., 2011; 
Carstensen et al., 2010). 
We also searched for changes of the inflammatory markers as consequence of the effects of 
the ingestion of L. reuteri on the gut peptides. An increase of GLP-2 secretion has been 
reported to enhance the expression of tight junctions in the intestinal wall, leading to 
decreased gut permeability and reduced leakage of endotoxin. These considerations lead to 
the assumption that circulating endotoxin levels are thought to be associated with gut 
permeability (Cani et al., 2009b; Pendyala et al., 2012; Erridge et al., 2007; Cani et al., 
2007b; Cani et al., 2008a). It has been suggested that low-grade metabolic inflammation 
driven by endotoxin translocation due to increased intestinal permeability is the proposed 
mechanism by which the microbiota may contribute to systemic inflammation in obesity 
(Caesar et al., 2010; Delzenne and Cani, 2011; Hotamisligil, 2006; Li and Hotamisligil, 2010). 
Strains of Lactobacillus spp. may have the capability to improve the intestinal integrity in 
rodents, which may diminish the LPS-leakage from the gut to the circulation, and thereby 
reduce the systemic concentrations of inflammatory markers such as cytokines (Mao et al., 
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1996; Luyer et al., 2005; Paturi et al., 2008). In our study however, LPS and systemic 
cytokine concentrations remained stable.  
In an open-label randomized pilot trial, Leber et al. showed that the probiotic strain L. casei 
did not affect the gut permeability, but rather lead to a slight increase of the LPS-binding 
protein (LBP) and the hsCRP levels after three months of treatment (Leber et al., 2012). 
Interestingly, we detected a positive correlation of LPS with BMI before L. reuteri 
administration that was lost after intervention suggestive of potential changes of LPS 
translocation from the gut to the systemic circulation. 
 
Effects of L. reuteri on intestinal permeability 
Increased intestinal permeability is associated with increased translocation of endotoxins 
released from the gut microbiota into the systemic circulation. Further, in animal models a 
link between increased plasma endotoxin levels, and obesity and insulin resistance has been 
described (Cani et al., 2007a; Vajro et al., 2013; Scaldaferri et al., 2012; Teixeira et al., 
2012).  
However, the integrity of the intestinal barrier in vivo is difficult to measure and as already 
mentioned in the section ‘material and method’ there was no thoroughly evaluated and 
validated assay available to measure changes on a physiological level of intestinal 
permeability (A. Fasano, personal communication). Therefore, the conclusion that the 
detected tendency of reduced LPS translocation from the gut to systemic circulation is 
associated with changes in the intestinal permeability is highly speculative and needs to be 
addressed in further studies. These clinical trials should take the potential changes in the 
intestinal permeability by Lactobacillus (Leber et al., 2012) into account and focus on 
additional validated surrogate parameter along with systemic endotoxins levels.  
Up to now, Ouwehand et al. reported that the ingestion of Lactobacillus acidophilus NCFM in 
combination with lactitol over 2 weeks altered the levels of Spermidine, a marker for an 
improved mucosal integrity and intestinal motility in healthy elderly subjects (Ouwehand et 
al., 2009). In contrast, in an open-label randomized pilot trial, Leber et al. showed that the 
probiotic strain L. casei does not affect the gut permeability in patients with metabolic 
disorders (Leber et al., 2012). Thus, these initial but conflicting evidence, whether the 
beneficial effects of probiotic microorganisms on intestinal barrier as reported in animal 
models (Wagnerberger et al., 2012; O'Hara and Shanahan, 2007; Iacono et al., 2011) and in 
vitro (Nissen et al., 2009) also occur in human subjects needs to be addressed in further 
clinical trials.  
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Effects of probiotic modulation of gut microbiota on adipokines 
The two adipokines leptin and adiponectin are secreted by the white adipose tissue that has 
the capability to regulate insulin sensitivity (Xie et al., 2008) and participate in whole-body 
metabolism by affecting energy balance and glucose metabolism (Soodini, 2004; Lee et al., 
2011; Morton and Schwartz, 2011). In obese mice, the modulation of gut microbiota 
improves leptin sensitivity, glucose homeostasis, and enteroendocrine cell activity (Everard 
et al., 2011). In addition, leptin has also been found to stimulate GLP-1 release from the 
human and rodent L-cells, and this effect is abolished in leptin-resistant diet-induced obese 
mice (Anini and Brubaker, 2003).  
Further, leptin reduces intestinal mucosal adherence and translocation of bacteria in rodents, 
since in the absence of leptin, mice are obese and dramatically inflamed in the mesenteric 
adipose tissue (Amar et al., 2011). Lipopolysaccharide, derived from the gut bacteria, 
contributes to systemic inflammation and may contribute to impaired insulin sensitivity in 
humans. Whether leptin might be mechanistically involved in the LPS-mediated systemic 
inflammation derived from the gut microbiota and thereby contributes to impaired insulin 
sensitivity in human subjects needs to be investigated. In our clinical trial, leptin correlated 
positively with LPS in lean and obese subjects, and this association persisted after 
adjustment for BMI. Furthermore, leptin correlated inversely with intestinotrophic GLP-2, 
peripheral insulin sensitivity and positively with pro-inflammatory cytokines. Further, our 
study in healthy lean and obese subjects with normal glucose tolerance showed that 
ingestion of L. reuteri did not affect leptin and adiponectin, body mass, glucose tolerance or 
insulin sensitivity.  
 
L. reuteri administration is associated with constant body weight and resting energy 
expenditure 
Although our study failed to detect physiological consequences like improved insulin 
sensitivity, glucose tolerance and body weight, of an increased incretin, insulin and C-peptide 
response in the L. reuteri treated group, these cannot be excluded. With a treatment duration 
of 4 weeks, our study was not designed to test for long-term effects. In this context, it is 
noteworthy that two trials of long-term probiotic ingestion did observe decreased body weight 
and fat mass. Chang et al. found reduced body weight and BMI upon 8 week of intervention 
with a probiotic yogurt supplemented with a mixture of different bacterial strains in 101 
healthy non-obese Korean subjects (Chang et al., 2011). Kadooka et al. reported a 
regulation of abdominal adiposity and body weight lowering effects by probiotics in 87 adults 
with tendencies of obesity (Kadooka et al., 2010). 
The body weight of lean and obese subjects included in our study remained stable upon 
treatment with L. reuteri or placebo. Likewise, resting energy expenditure (REE), measured 
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by indirect calorimetry, remained stable. Furthermore, the REE and body weight before and 
after intervention showed an inverse intra-individual correlation with the AUCs of GLP-1 and 
GLP-2. These findings suggest that obese subjects have lower incretin concentrations 
compared to lean subjects during the glucose tolerance test. Differences with regard to L. 
reuteri treatment, however, have not been detected concerning to REE, neither in lean nor in 
obese subjects. 
 
Strengths and limitations of the study 
The limitations of our study were the small size of the cohort and the rather short intervention 
period and did not investigate patients with diagnosed diabetes. However, in contrast to other 
studies in the field, in which healthy and diseased subjects were analysed together, we 
investigated healthy, non-diabetic subjects and performed detailed metabolic 
characterization. We used strongly validated methods including the gold standard the 
hyperinsulinemic-euglycemic clamp test with isotopic dilution to assess tissue specific insulin 
sensitivity and substrate oxidation, the OGTT to determine the glucose tolerance, OGIS, and 
detailed calculations on insulin sensitivity and β-cell function. 
 
One hypothesis is, that bacterial fermentation in the gut deliver SCFA, that may in turn 
modulate the release of gut hormones controlling insulin release and appetite (Tolhurst et al., 
2012; Tarini and Wolever, 2010; Freeland et al., 2010). Short chain fatty acids play an 
important role in the development of type 2 diabetes, since it has been shown that butyrate-
producing bacteria are decreased in patients with type 2 diabetes and subjects with 
metabolic disorders (Qin et al., 2012; Vrieze et al., 2012). As we did not investigate SCFA, 
this is one limitation of our study and it remains unclear, whether SCFA could be responsible 
for the changes of insulin secretion and incretin concentrations observed in our study. The 
measured FFA and triglycerides did not change upon intervention in our study cohort. 
However, the incretin effect was improved by the intervention which may reflect the known 
effects of gut microbiota and their fermentative end products, the SCFA. 
 
The strength of our clinical trial is that we showed for the first time, that probiotic L. reuteri 
administration increased glucagon like peptides, insulin and C-peptide responses in glucose-
tolerant human subjects suggestive of an incretin-mediated insulin release, however without 
improvement of glucose homeostasis and insulin sensitivity. 
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Conclusion 
 
Subjects who ingested the probiotic strain L. reuteri or placebo showed good compliance, 
which was confirmed by treatment adherence and the detection of L. reuteri in the fecal 
samples of those subjects who received L. reuteri, while samples of subjects receiving 
placebo remained negative. The intake of L. reuteri was positively associated with L. reuteri 
containing feces and harmless changes in gut microbiota composition. Ingestion of L. reuteri 
showed no side effects, and was well tolerated.  
As expected, lean and obese non-diabetic subjects differed with regard to body weight, 
whole body insulin sensitivity, hepatocellular lipid content and LPS concentrations before the 
intervention. The ingestion of L. reuteri over four weeks changed neither body mass and 
composition, nor ectopic fat content in particular liver fat content. Further, L. reuteri did not 
affect whole body and hepatic insulin sensitivity, systemic inflammation or oxidative stress 
but increased the release of C-peptide, insulin, and the gut hormones GLP-1 and GLP-2 in 
lean and obese glucose tolerant subjects.  
These alterations of increased release of C-peptide, insulin, and the gut hormones GLP-1 
and GLP-2 were detectable in non-diabetic humans after a rather short treatment period of 
only four weeks. Whether the moderate effects are continuable or enlarged after longer 
treatment periods remains to be addressed in long-term intervention studies.  
Compared to findings from the literature, our study showed no effects of the ingestion of L. 
reuteri on peripheral and hepatic insulin sensitivity or related parameters such as body mass, 
ectopic fat content, and systemic inflammation or oxidative stress. But the increased insulin, 
C-peptide and glucagon-like peptides concentrations, suggest that the intervention has 
metabolic effects, even detectable in this small cohort of glucose tolerant subjects. 
Therefore, a more pronounced effect may be detectable in a more homogenous study group 
or a group with impaired glucose tolerance.  
The observations implicate that there is a great potential of the administration of probiotics as 
a simple and efficient strategy to develop preventive and therapeutic approaches for type 2 
diabetes. Thus, probiotic-mediated insulin secretion could serve as a novel therapeutic tool, 
which might be helpful in patients with type 2 diabetes or subjects with impaired glucose 
tolerance. However, further studies are required to establish, whether long-term treatment 
with L. reuteri or treatment of humans with overt diabetes mellitus will yield results that are of 
clinical benefit for the subjects with diabetes mellitus. 
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Outlook 
 
The composition of the gut microbiota may affect various disorders like obesity, disturbed 
glucose homeostasis including insulin resistance and diabetes. The identification of different 
enterotypes is one way to look at and to classify people. Based on these findings, modulation 
of the gut microbiota can be considered as an option to prevent and treat diseases. To date 
the use of prebiotics and probiotics is one tool for educating the immune system and to 
prevent the development of metabolic disorders. These results are mainly established in 
animal models and many questions remain to be answered specially for human subjects.  
The many reported heterogeneous findings may be attributed to factors such as different 
strains and dosages of probiotics, clinical characteristics of participants, duration of treatment 
period, sample size and study design. The present study demonstrates in a first step, that 
ingestion of L. reuteri modulates the secretion of insulin, C-peptide and the gut hormones 
GLP-1 and GLP-2 in humans, whereas no effects were observed on insulin sensitivity and 
parameters influencing insulin sensitivity such as body mass, ectopic fat content, and 
systemic inflammation or oxidative stress.  
Since the modulation of gut microbiota and successional gut hormones not only affect gut 
physiology, but also glucose homeostasis, appetite and fat metabolism, the idea of 
administration of probiotic strains, who are able to increase incretin mediated insulin release 
would be an attractive area for drug development. The understanding on molecular 
mechanisms would facilitate this process. Therefore we have to think now more deeply how 
we can change the microbiome.  
A personalized gut microbiota management may be an option for the prevention or even 
treatment of obesity, metabolic disorders and diabetes. However, how an efficient modulation 
of the gut microbiota of the host either by transplantation, administration of pre-, pro- or 
synbiotics or substitution with artificial optimized gut microbiota is optimally achieved needs 
to be investigated in further studies.  
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